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1. EXECUTIVE SUMMARY 
 
Buruli ulcer disease is a serious necrotizing skin infection caused by the environmental pathogen 
Mycobacterium ulcerans and represents the third most common mycobacterial infection worldwide after 
tuberculosis and leprosy.  This disease, if left untreated, can lead to disfiguring and disabling lesions, 
particularly affecting young populations in resource-poor settings.  Antibiotic treatment 
recommended by the World Health Organization (WHO) since 2004 has simplified the delivery of 
care for Buruli ulcer and provided solid evidence that early and limited lesions can be effectively 
treated with antibiotics alone.  However the current recommendations still present significant 
challenges including the use of aminoglycosides requiring intramuscular injection.  These drugs are 
difficult and costly to administer in resource-poor settings and have significant side effects that 
present major obstacles to implementation.  Therefore, there is an urgent need to identify alternative 
oral regimens that can be effective, short-course, all-oral, compatible for use in pediatric population 
and have few drug-drug interactions with antiretrovirals (ARVs). 
 
The results of a literature review identified several drugs and drug candidates that demonstrated 
potential efficacy against Buruli ulcer with more attractive administration and toxicity profiles.  
However, data are fragmented, limiting the rigorous conclusions that can be drawn.  Although 
recent studies indicate that a fully orally-administered treatment regimen such as clarithromycin-
rifampicin may be equally effective as regimens containing aminoglycosides, further research is 
critically needed to identify and evaluate other treatment options.  The anti-tuberculosis drug 
research and development pipeline also represents an important and potentially rich source of novel 
compounds for Buruli ulcer treatment.  
 
In order to optimize therapy for patients with Buruli ulcer in low-resource settings,  
 
Researchers and pharmaceutical companies should: 
1. Systematically evaluate potential drugs for efficacy against M. ulcerans, including drugs developed for other 
purposes and those that have been abandoned for other indications. 
2. Support clinical trials to evaluate the most promising candidate drug combinations, especially those that are 
all-oral, have minimal side effect profiles and offer shorter duration of therapy. 
3. Ensure that drugs for Buruli ulcer are both available and affordable for those living in resource-poor 
environments. 
WHO should: 
1. Rapidly evaluate the changing clinical evidence base and create evidence-based guidelines to enable countries 
and health workers to continually refine the treatment of Buruli ulcer. 
2. Ensure that components of new and optimal therapies are included in the Essential Medicines List.  
Endemic Countries should:  
1. Invest in educational campaigns to promote early diagnosis along with treatment programs for Buruli ulcer. 
2. Ensure that components of Buruli ulcer therapy are included in national Essential Medicines Lists. 
3. Support research efforts to test the efficacy and safety of new drug candidates and combination drug regimens. 
 
 
2. INTRODUCTION 
 
Buruli ulcer disease, a cutaneous infection caused by the environmental pathogen Mycobacterium 
ulcerans, is associated with significant morbidity and functional disability worldwide [1-3].  Reported 
in over 30 countries, mainly in the tropical and subtropical regions of Africa, Latin America, Asia 
and Western Pacific, it represents the third most common mycobacterial infection after tuberculosis 
and leprosy (Figure 2.1).  It is endemic primarily to rural and remote regions where populations have 
limited access to medical care [3]. 
 
Figure 2.1 – Distribution of Buruli ulcer, worldwide, 2011. Figure courtesy of WHO. 
 
 
Buruli ulcer disease largely affects children, with the median age of patients around 15 years.  
Although it initially starts as a painless nodule in the skin, the disease can progress if untreated to 
form extensive, ulcerative lesions, often involving the extremities and leading to significant 
functional limitations [4].  These lesions are classified according to their size and appearance, with 
implications for their management (Table 2.1) [5]. 
 
Until recently the mainstay of treatment of Buruli ulcer disease had been wide surgical excision of 
the cutaneous lesion(s) [1,2,6].  However, there are significant challenges to the implementation and 
effectiveness of this approach in the primarily resource-poor settings where Buruli ulcer disease is 
endemic.  Indeed surgery is accessible to only a small fraction of the population at risk for Buruli 
ulcer.  Moreover, surgical management has limited efficacy with recurrence rates ranging from 6 to 
17%, in part due to the difficulty of completely eradicating the infection with excision alone [7-11].  
Lastly, ulcer involvement can include the face, eyes or other structures, where excision may be 
challenging or associated with disfiguring or disabling consequences. 
Table 2.1 – WHO Classification of Buruli ulcer disease [5]. 
 
Early attempts to explore the use of antibiotic treatment in the management of Buruli ulcer led to 
inconclusive and disappointing results, discouraging the use of chemotherapeutic approaches [12-18].  
The apparent lack of efficacy of antibiotics in these earlier studies may have been compromised by 
the paradoxical development of new lesions or increased size of existing lesions during antibiotic 
treatment.  This phenomenon has recently been recognized as an immune-mediated paradoxical 
reaction due to mycobacterial killing and is not believed to represent worsening disease or relapse 
[19-21].  In addition, several in vitro and in vivo studies have shown that antibiotics do have significant 
bacteriostatic or bactericidal activity against the causative agent, M. ulcerans [14,15,22-36].  The 
combination of rifampicin with an aminoglycoside, such as streptomycin or amikacin, consistently 
emerged as the most effective against M. ulcerans infection in murine models [24,37,38]. 
 
Based on the available data, the 6th World Health Organization (WHO) Advisory Committee on  
M. ulcerans disease in 2004 recommended for the first time an antimicrobial regimen for Buruli ulcer 
treatment, comprised of 8 weeks of rifampicin and streptomycin [5].  While subsequent studies have 
demonstrated the clinical efficacy of this regimen in treating early stages of disease, larger lesions 
have continued to require surgical excision [39-41].  There are additional limitations to the current 
treatment recommendations, including the challenges of intramuscular drug administration in 
endemic areas and the potential toxicities associated with aminoglycosides.  Thus, despite recent 
advances in the management of Buruli ulcer disease, the identification of alternative antimicrobials 
or novel agents with simplified delivery of care remains a high priority.  Ideally, the treatment 
regimen for Buruli ulcer should be fully orally administered, appropriate for pediatric or pregnant 
patients, and well-tolerated with minimal side effects.  Further characteristics of the ideal and 
acceptable end-user requirements for Buruli ulcer treatment are detailed in Table 2.2. 
 
With these goals in mind, we sought to summarize the available information about potential 
chemotherapeutic agents for Buruli ulcer as well as propose a research agenda aimed at identifying 
improved treatment regimens for Buruli Ulcer. 
Category Description 
I Small, early lesion – e.g. nodule, papule, plaque, ulcer < 5 cm in diameter 
II Nonulcerative or ulcerative plaques and edematous forms 
 
Large ulcerative lesions ( between 5 and 15 cm in diameter) 
 
Lesions in the head and neck 
III Lesions > 15 cm in diameter 
 
Disseminated/mixed forms (e.g. osteitis, osteomyelitis, joint involvement) 
 
Table 2.2 –Proposed ideal and acceptable end-user requirements for Buruli ulcer chemotherapy. 
Profile Ideal Acceptable 
Target population Acceptable for special populations: 
 Pregnant and lactating women, 
 Pediatric patients, 
 Immunocompromised patients 
Acceptable for special populations: 
 Pediatric patients, 
 Immunocompromised patients 
Efficacy*  For lesions with cross-sectional 
diameter of ≤10 cm: Relapse-free cure 
rate without excision surgery >95% 
 For lesions with cross-sectional 
diameter of >10 cm: Reduction in need 
for and extent of surgical interventions.  
Relapse-free cure rate >95% 
 For lesions with cross-sectional diameter 
of ≤10 cm: Relapse-free cure rate 
without excision surgery >90% 
 For lesions with cross-sectional diameter 
of >10 cm: Reduction in need for and 
extent of surgical interventions.  
Relapse-free cure rate >90% 
Drug-drug 
interaction 
 No drug-drug interactions with ARVs 
(e.g. no interaction in addition to 
existing interactions between rifampicin 
and ARVs) 
 Some drug-drug interactions, but can be 
used with dose adjustments 
Formulation  Oral administration 
 Small-sized or dispersible tablets (for 
pediatric use) 
 Different fixed dosages (i.e. 
25mg/50mg/100mg) 
 FDC or blister-packs  
 Oral administration 
 Small-sized or dispersible tablets (for 
pediatric use) 
 Possible scoring for weight-based dosing 
(i.e. double-scored 100mg tablet)  
Dosing frequency 
and duration 
 Once daily 
 Duration <8 weeks 
 Once daily 
 Duration ≤ 8 weeks 
Safety/Tolerability  Well-tolerated (minimal GI distress). 
 Minimal dosing instructions / 
specifications (e.g. take with food, take 
on empty stomach, etc…) 
 No laboratory monitoring 
 Well-tolerated (minimal GI distress). 
 No laboratory monitoring 
Stability  No cold chain requirement 
 Minimum 4-year shelf life at room 
 No cold chain requirement 
 Minimum 2-year shelf life at room 
temperature in tropical settings temperature in tropical settings 
Price  Half the current price of antimicrobial 
treatment (including syringes) or less:  
< US$50 for an adult patient 
 Equal to or less than the current price of 
antimicrobial treatment (including 
syringes): < US$100 for an adult patient 
Abbreviations: GI, gastrointestinal; FDC, fixed dose combination; ART, antiretroviral therapy; US$, U.S. dollars 
* Rigorous evaluation of treatment efficacy is currently challenging due to lack of reliable biomarkers for treatment 
response.  Thus, efficacy has been described using the same criteria applied in recently completed and ongoing clinical 
trials on Buruli ulcer treatment. 
 
3. METHODOLOGY 
 
We searched the following databases using the search terms described in Appendix Table A.1: 
PubMed, EMBASE, Scopus, WHO Global Health Library, CAB Abstracts and Cochrane Library.  
As a complementary strategy, individual searches were performed to identify articles testing the 
activity against Mycobacterium ulcerans of specific drugs with known activity against other 
mycobacterial species.  Using the ClinicalTrials.gov registry, relevant clinical trials focusing on Buruli 
ulcer disease management were identified.  We also screened abstracts submitted to relevant 
international conferences and meeting proceedings.  While there were no restrictions on publication 
date or type, only articles in English, French and Italian were included for review.  Articles published 
or available as of December 31, 2012 were accessed.  Both clinical and laboratory studies were 
reviewed, including randomized clinical trials, observational studies, case reports or series, as well as 
experimental studies of in vitro and in vivo activity against Mycobacterium ulcerans.  Articles were 
excluded that did not establish microbiological diagnosis of M. ulcerans as the causative agent or 
specifically focus on antimicrobial interventions.  References of all included articles were searched 
for additional studies.  Data were extracted by two reviewers (M.C. and C.G.). 
 
4. IDENTIFICATION OF POTENTIAL ANTIBIOTICS FOR BURULI ULCER 
 
Due to the similarity of genomic sequences among members belonging to the same genus, there is a 
high probability that molecular targets of different drugs are conserved, such that the same drugs 
can be active against different members of the same genus.  Mycobacterium ulcerans has been shown to 
be closely related taxonomically to M. tuberculosis and other mycobacterial species (Figure 4.1) [42], 
suggesting that drug molecular targets may be conserved among these mycobacterial species. 
 
All drugs with reported anti-mycobacterial activity, including those not routinely used in the clinical 
management of mycobacterial infections, are listed in the Appendix (see Appendix Table A.2).  In 
addition, new drug candidates in clinical development as anti-tuberculosis drugs are included 
 
We explored the potential applicability of drugs currently used in the treatment of various 
mycobacterial infections in treating Buruli ulcer disease.  All available information on the in vitro, in 
vivo and clinical applications of these existing and new drugs in treating M. ulcerans infection are 
reviewed in detail in the following section. 
 
 
Figure 4.1 Phylogenetic tree of slow growers members of the genus Mycobacterium. Strict consensus of the 230 
most parsimonious trees using Paup 4.0b10 (heuristic search, gaps = fifth state) from the 1286 aligned nucleotides of 
the 16S rRNA DNA sequence. Sequenced genomes are highlighted in yellow. Underlined species are considered 
pathogens. The members of the M. tuberculosis complex and the M. avium complex are indicated. The divisions 
between the normal helix 18, long helix 18 and extended helix 18 of the 16S rRNA gene sequence are indicated 
(Figure courtesy of van Pittius, Sampson, Lee, Kim, van Helden & Warren; Van Pittius et al, BMC Evolutionary 
Biology 2006, 6:95) 
 
 
 
5. PROSPECTS FOR BURULI ULCER TREATMENT 
 
Based on the scientific work carried out so far, we have classified these antimicrobial agents into 
four categories: 
 Antibiotics with clinical application for the treatment of Buruli ulcer 
 Antibiotics suitable for or that could be suitable for the treatment of Buruli ulcer but require 
further investigation 
 Antibiotics of unclear value due to lack of sufficient data 
 Antibiotics that are not suitable for the treatment of Buruli ulcer 
5.1 Antibiotics with clinical application for treatment of Buruli ulcer 
5.1.1 Clinical application of combination antibiotic regimens 
 
Data on the clinical activity of available drugs against M. ulcerans are presented in Table A.3 of the 
Appendix.  Since the WHO formally published its recommendations for combination antibiotic 
therapy with rifampicin and streptomycin in managing Buruli ulcer disease, several studies have 
demonstrated the effectiveness of this regimen.  A pilot study in Ghana sponsored by the WHO 
established that rifampicin-streptomycin was active against Buruli ulcer disease in patients [39].  This 
clinical trial demonstrated that, after daily treatment with rifampicin-streptomycin for at least 4 
weeks, M. ulcerans could no longer be cultured from the lesions. Antibiotic treatment also reduced 
the surface area of most lesions by greater than 50%, thus allowing for less extensive surgical 
excision.  Chauty and colleagues presented data on a cohort of patients in Benin who were treated 
for Buruli ulcer disease [41].  Of the 215 patients with healed lesions after 1 year of follow-up, nearly 
half (47%) had received rifampicin-streptomycin alone for 8 weeks without the need for surgery.  
Additional studies have confirmed the clinical effectiveness of rifampicin-streptomycin alone and in 
combination with surgery for Buruli ulcer treatment [43-48]. 
 
Alternative antibiotic regimens also have been used clinically with reported success in treating Buruli 
ulcer disease.  However, further systematic investigation is needed to establish these regimens as 
equivalent or possibly superior to the current standard of care.  Several case reports have 
documented the successful replacement of the aminoglycoside with a macrolide clarithromycin in 
combination with rifampicin for Buruli ulcer treatment.  Dossou et al [49] reported the successful 
treatment of Buruli ulcer in a pregnant woman with rifampicin and clarithromycin for 8 weeks, and 
Gordon et al [50] treated two pediatric patients with individualized durations of rifampicin and 
clarithromycin syrup.  Subsequent clinical studies have been undertaken to systematically 
demonstrate the efficacy of clarithromycin in treating Buruli ulcer disease.  In the BURULICO trial 
conducted by Nienhuis and colleagues [40], patients were randomized to receive either rifampicin-
streptomycin for 8 weeks or rifampicin-streptomycin for 4 weeks followed by rifampicin-
clarithromycin for the remaining 4 weeks.  Participants were followed for one year, during which 73 
(96%) participants in the 8-week streptomycin group and 68 (91%) in the 4-week streptomycin plus 
4-week clarithromycin group had healed lesions, a non-statistically significant difference.  No 
participants with healed lesions had disease recurrence during the study period.  Based on these data, 
the authors proposed that 4 weeks of streptomycin and rifampicin followed by 4 weeks of 
rifampicin and clarithromycin had similar efficacy to 8 weeks of streptomycin and rifampicin.   
 
Chauty et al conducted a pilot study in which 30 patients in Benin were treated with rifampicin-
clarithromycin for 8 weeks, all of whom had healing within 12 months of treatment initiation 
without any observed relapses in that 1 year of follow-up [51].  While 15 patients in that study 
required surgery, 8 of 10 patients with category I ulcerative lesions and 5 of 11 patients with larger 
lesions were cured with chemotherapy alone.  Currently, a WHO-sponsored, randomized multi-
center trial is being rolled out to directly compare 8 weeks of rifampicin and clarithromycin to 8 
weeks of rifampicin and streptomycin in Buruli ulcer treatment [52]. 
 
Recently, O’Brien et al presented data on 133 patients with Buruli ulcer disease treated between 1998 
and 2010 and found no difference in treatment success rates for antibiotic combinations containing 
fluoroquinolones compared with those not containing a fluoroquinolone[53].  The most common 
initial antibiotic regimens were rifampicin and ciprofloxacin (61%) and rifampicin and 
clarithromycin (23%).  Despite several published reports of the use of fluoroquinolones in the 
treatment of Buruli ulcer disease, only a small pilot study of 30 patients has been conducted to study 
the use of fluoroquinolones [54].  In this study, patients were treated with rifampicin-streptomycin 
daily, rifampicin-streptomycin on alternate days, or rifampicin-moxifloxacin daily.  This study 
showed encouraging results for the use of fluoroquinolones.  Daily rifampicin-streptomycin 
treatment was more rapidly effective, with 9 out of 17 patients treated with this combination healed 
at 4 weeks compared to 1 out of 6 patients treated with rifampicin-moxifloxacin.  However, after 8 
weeks of treatment, comparable percentages of patients had healed lesions in the groups treated with 
rifampicin-streptomycin (20 of 24 patients, 2 lost to follow-up) and rifampicin-moxifloxacin (5 of 6 
patients).  Furthermore, a retrospective review of Buruli ulcer disease management in southeastern 
Australia between 1998 and 2004 demonstrated that the addition of antibiotic therapy to surgical 
management significantly improved treatment success rates [55].  Of the various antibiotic regimens 
used, the combination rifampicin-ciprofloxacin had 100% treatment success and tolerability, with no 
patients prematurely stopping treatment. 
 
Despite the documented in vitro efficacy of amikacin against M. ulcerans, clinical studies have offered 
mixed results regarding its effectiveness.  A randomized controlled trial of 50 patients in Côte 
d’Ivoire with Buruli ulcer disease was performed to evaluate the efficacy of combination rifampicin-
amikacin along with enoxaparin (a low molecular weight heparin product) for 3 months versus 
wound care alone [56].  In this study, 20 (80%) patients treated with antibiotics did not require 
surgery, compared to 0 of 25 patients treated with local wound care.  However, clinical data 
published by O’Brien et al [55] demonstrated that the use of amikacin was associated with reduced 
treatment effectiveness and significant toxicity, particularly for elderly patients. 
 
5.1.2 Laboratory-based data on individual antibiotics 
 
The dual antibiotic regimens pursued in the clinical studies described above have been motivated by 
in vitro and in vivo data establishing the anti-mycobacterial activity of the individual agents as well as 
in combination.    
 
Rifampicin 
The in vitro and in vivo activity of rifampicin against M. ulcerans has been extensively documented, and 
several independent publications from different laboratories consistently report a high bactericidal 
activity of rifampicin in animal models of Buruli ulcer disease [24,25,33,34,36,57].  When 
administered as monotherapy for 8 weeks, rifampicin is able to clear the footpads of M. ulcerans-
infected mice, indicating strong bactericidal activity in vivo [33,34].  Common adverse effects of 
rifampicin, such as nausea, seldom result in its discontinuation.  However, there are treatment-
limiting adverse effects including drug-induced hepatitis or a “flu-like” syndrome [58].  Rifamycins 
are also associated with significant drug-drug interactions as a result of their ability to induce 
metabolic enzymes, particularly cytochrome P450 (CYP) 3A, in the gut and liver.  Drug-drug 
interactions between rifampicin and antiretroviral drugs [59], however, significantly complicates the 
treatment of Buruli ulcer disease in patients co-infected with HIV. 
 
Fluoroquinolones 
M. ulcerans has been shown to be susceptible in vitro to fluoroquinolones [27,28,34,57].  Several 
fluoroquinolones, including levofloxacin, moxifloxacin, ofloxacin and sitafloxacin, have been tested 
in the animal footpad model for activity against Buruli ulcer disease.  Levofloxacin and moxifloxacin 
demonstrated bacteriostatic activity in the mouse footpad preventive model [23].  When 
moxifloxacin was tested in the mouse footpad curative model, the proportion of mice with culture-
positive footpads among those that received moxifloxacin as monotherapy was significantly greater 
than among mice administered rifampicin, streptomycin or amikacin as monotherapy [33,34].  These 
data indicate that moxifloxacin is less bactericidal than rifampicin or the aminoglycosides. 
 
The activity of ofloxacin and sitafloxacin, either as monotherapy or in combination with rifampicin, 
in the mouse footpad model has also been investigated [29].  Despite the small number of mice in 
the studies limiting the statistical interpretation, the results suggested that sitafloxacin has strong 
bactericidal activity even at low doses.  When used as monotherapy, a low dose of sitafloxacin (with 
administration starting 4 weeks after infection) was sufficient to obtain culture-negative footpads in 
all treated mice after 4 weeks of treatment.  Footpads of mice remained culture-negative at 2 weeks 
of post-treatment follow-up.  In order to obtain comparable results with ofloxacin treatment, a four-
fold higher dose of ofloxacin had to be administered to mice.  Thus, these preliminary results 
indicated that sitafloxacin may have great potential as an effective drug for Buruli ulcer disease. 
However, an important caveat is that sitafloxacin has been shown to have significant phototoxicity 
in Caucasian populations, which may limit its clinical applicability [60]. 
 
Macrolides 
Clarithromycin and azithromycin are macrolides commonly used in the treatment of Mycobacterium 
avium complex infections [61].  M. ulcerans is susceptible to clarithromycin in vitro, with MICs on 
isolates and strains ranging from 0.125 to 2 mg/ml at pH 6.6 and from <0.125 to 0.5 mg/ml at pH 
7.4 [25,35,62].  When tested in the mouse footpad preventive model, clarithromycin showed weak 
bactericidal activity.  In mice infected on day 1 and started on clarithromycin treatment on day 7, 
footpad swelling was observed on average at week 10.  In contrast, footpad swelling started at week 
12 in mice treated with rifampicin and week 15 in mice treated with an aminoglycoside [23,25].  
Bentoucha and collaborators[23] compared the activities of clarithromycin, azithromycin, 
moxifloxacin and levofloxacin using the mouse footpad preventive model.  In the control group of 
untreated mice, swelling of 50% of footpads occurred by 6 weeks, while swelling of 50% of the 
infected mice footpads occurred by 7 weeks in mice treated with daily levofloxacin (200mg/kg), by 8 
weeks in mice treated with daily azithromycin (100 mg/kg) and those treated with daily moxifloxacin 
(100mg/kg), and by 11 weeks in mice treated with daily clarithromycin (100 mg/kg).  In comparison, 
mice treated with rifampicin, amikacin and streptomycin developed swelling of 50% of mice 
footpads by 13, 17 and 25 weeks, respectively.  These data suggest that: i) clarithromycin has 
stronger anti-mycobacterial activity than the fluoroquinolones; and ii) levofloxacin activity is slightly 
weaker than that of moxifloxacin.  Among the macrolides, azithromycin exhibited weaker, 
bacteriostatic activity against M. ulcerans compared to clarithromycin but its activity was comparable 
to that of moxifloxacin.  In a study published by Ji and colleagues [33], clarithromycin activity was 
tested in the mouse footpad curative model and compared with the activity of rifampicin, 
streptomycin and moxifloxacin.  While data generated in the mouse preventive model suggest that 
clarithromycin has stronger activity compared to moxifloxacin, data in the mouse curative model 
suggest that these two drugs have comparable activity.  Indeed, after 4 weeks of treatment the mean 
colony forming unit (CFU) counts of mice treated with clarithromycin alone was similar to that of 
mice treated with moxifloxacin monotherapy.  In addition, the reduction in CFU counts in these 
two treatment groups was significantly smaller than that seen in mice treated with rifampicin alone. 
 
In considering clarithromycin as a possible option for Buruli ulcer chemotherapy, it is important to 
investigate possible drug-drug interactions that can occur when clarithromycin is used in 
combination with rifamycins.  Indeed, clarithromycin is metabolized by the CYP3A enzyme pathway, 
and rifampicin (and to a lesser extent rifabutin) has been showed to induce clarithromycin 
metabolism, leading to reduced serum levels [63,64].  Alffenaar et al [65] studied the 
pharmacokinetics of rifampicin and clarithromycin in patients enrolled in the BURULICO trial and 
found that co-administration of these two drugs resulted in higher levels of rifampicin exposure 
compared to the rifampicin-streptomycin group and lower levels of clarithromycin exposure.  Of 
note, low-dose clarithromycin was administered in the BURULICO trial (7.5 mg/kg/day), 
suggesting that higher doses of clarithromycin (7.5 mg/kg twice daily) could be more efficacious. 
5.1.3 Laboratory-based data on combination antibiotic regimens 
 
The combination of rifampicin with either streptomycin or amikacin demonstrated strong 
bactericidal activity in animal models, with 100% cure rates after 8 weeks of treatment.  In addition, 
the rifampicin-moxifloxacin regimen had comparable results to the rifampicin-aminoglycoside 
combinations [33,34].  No relapses were observed during 28 weeks of post-treatment follow-up in 
mice that received 8 weeks of rifampicin-streptomycin in two studies conducted in 2007 and 2008.  
In comparison, mice treated with 8 weeks of rifampicin-moxifloxacin had no relapses or 1 relapse in 
20 mice (5% relapse rate) during the 28-week follow-up period [32,33]. 
 
Clarithromycin has also been tested in conjunction with rifampicin with conflicting results regarding 
its comparable activity to a rifampicin-aminoglycoside regimen.  One found that the combination 
rifampicin-clarithromycin-sparfloxacin was less bactericidal than rifampicin-amikacin; but of note, 
the triple combination regimen had greater bactericidal activity than rifampicin monotherapy [24]. 
Subsequently two studies in mouse footpad curative models assessed the bactericidal activity and the 
relapse rate after treatment completion of the rifampicin-clarithromycin and rifampicin-moxifloxacin 
regimens compared to the rifampicin-streptomycin regimen [32,33].  Both studies demonstrated that 
the macrolide-containing regimen had similar activity to that of rifampicin-streptomycin.  In addition 
these studies showed that, although the rifampicin-clarithromycin regimen was slightly more active 
than the rifampicin-moxifloxacin regimen after 4 weeks of treatment, the two oral regimens had 
equivalent activity at treatment completion (after 8 weeks).  More recently, a study in the mouse 
curative model compared rifampicin-clarithromycin and rifapentine-clarithromycin regimens and 
demonstrated that the rifapentine-containing regimen is more active [22].  Taken together, these data 
support a role for clarithromycin in Buruli ulcer treatment and also indicate that moxifloxacin may 
be a valuable alternative to clarithromycin for an all-oral regimen. 
 
Moxifloxacin-clarithromycin, a non-rifampicin based regimen, has also been studied in the 
laboratory and shown to have limited activity.  While 8 weeks of rifampicin-streptomycin 
successfully sterilized all mice, the combination moxifloxacin-clarithromycin, despite demonstrating 
bactericidal activity, failed to render all inoculated footpads culture-negative after 8 weeks of 
treatment.  Furthermore, 59% of the mice treated with the oral regimen relapsed during the 28 
weeks of post-treatment follow-up [32].  
 
5.2 Antibiotics that are suitable for or could be suitable for treatment of Buruli ulcer 
There are several other classes of antimicrobials that are attractive candidates for treatment of Buruli 
ulcer disease.  Other drugs with features – such as oral administration and good safety profile – that 
make them attractive for Buruli ulcer treatment include other rifamycins, dapsone, epiroprim and 
bedaquiline, one of the newest anti-tuberculosis drugs in development. 
5.2.1 Other rifamycins (rifapentine, rifabutin) 
 
Rifapentine 
 
Rifapentine is an analogue of rifampicin that is characterized by a longer half-life (Table 5.2) and 
lower MIC for M. tuberculosis than rifampicin [58].  The increased bactericidal activity of a 
rifapentine-based regimen for TB can be explained largely by increased rifamycin exposure due to 
the long half-life of rifapentine [66].  In clinical trials testing once weekly rifapentine, the drug has 
been well tolerated and the rate of adverse reactions has been reported to be similar or lower than 
with twice weekly rifampicin [67,68].  
 
A possible role for rifapentine in the treatment of Buruli ulcer disease has been explored.  In mouse 
curative footpad models, treatment with rifapentine (administered either 5 days a week or twice a 
week) and rifampicin had similar levels of bactericidal activity [32].  In addition, Almeida and 
colleagues [22] demonstrated that rifapentine monotherapy had similar bactericidal activity to 
rifampicin-streptomycin. 
 
Rifapentine has also been studied in combination treatment regimens in animal models.  In mouse 
curative footpad models, the levels of bactericidal activity for the groups receiving twice weekly 
rifapentine in combination with either streptomycin or moxifloxacin did not differ significantly from 
the comparison groups receiving combination therapy with rifampicin 5 days a week [32].  Based on 
these data, the authors suggest that Buruli ulcer might be treated with twice weekly rifapentine in 
place of daily rifampicin, thereby simplifying the treatment regimen.  In addition, moxifloxacin may 
be preferred over streptomycin in combination with rifapentine because the longer half-life of the 
fluoroquinolone may make it more effective in preventing the selection of rifamycin-resistant strains.   
 
Of note, in the mouse model, combining clarithromycin with either rifampicin or rifapentine was 
associated with shorter median time to footpad swelling than monotherapy with both rifamycins.  
This was thought to be the result of reduced rifamycin absorption due to the higher doses of 
clarithromycin required in mice; separating the administration of the two antibiotics restored 
rifamycin absorption [22].  This is not anticipated to be of consequence clinically. 
 
Rifabutin 
 
Studies in the mouse footpad preventive model showed that the bactericidal activity of rifabutin 
against M. ulcerans is comparable to that of rifampicin [25].  As shown in Table 4.2, among the 
rifamycins, rifabutin has the lowest potential to induce CYP3A enzymes.  Rifabutin is considered as 
a possible alternative to rifampicin in the treatment of mycobacterial infections in patients co-
infected with HIV who receive boosted protease inhibitors [69]. 
 
 
Table 5.2 –Comparison of the interactions of rifamycins with cytochrome P450 (CYP) 3A.  Figure courtesy of 
Burman, Gallicano, & Pelloquin, 2001 [58]  
 
Interaction Rifampicin Rifapentine Rifabutin 
Major metabolic 
pathway 
Deacetylation; hydrolysis 
to formyl derivatives 
Deacetylation; hydrolysis 
to formyl derivatives 
CYP3A-mediated 
hydroxylation; deacetylation 
Serum half-life (h) 2-5 14-18 32-67 
Effect on CYP3A Pronounced Moderate Weak 
Auto-induction of 
metabolism 
Yes No Yes 
Example of CYP3A 
induction: effect on 
indinavir AUC 
92% decrease 70% decrease 34% decrease 
Change in AUC 
when given with a 
CYP3A inhibitor a 
No effect No effect 293% increase 
aFrom interaction studies with ritonavir (rifampicin and rifabutin) and indinavir (rifapentine). 
Abbreviations: AUC, area under the concentration-time curve 
 
5.2.2 Dapsone 
 
Dapsone has been shown to have in vitro MIC values on clinical isolates and strains between 2.0 and 
4.0 mg/ml against M. ulcerans.  The activity of dapsone in a mouse footpad preventive model was 
first studied in 1965 by Pattyn and Royackers [70].  Mice footpads were inoculated with M. ulcerans 
(day 0) and treated for 48 days starting from day 1.  Both dapsone and streptomycin were able to 
prevent footpad lesions.  However, while all mice (n=8) treated with streptomycin were still disease-
free after 36 days of post-treatment follow-up, all those treated with dapsone (n=8) developed 
lesions in the follow-up period. 
 
In 2002, a randomized, placebo-controlled pilot study of 30 patients was conducted to assess the 
efficacy of 8 weeks of rifampicin-dapsone in the treatment of Buruli ulcer disease [18].  Although the 
experimental group had a median decrease in ulcer size of 14 cm2 compared to 2.5cm2 in the control 
group, there were no significant differences in treatment outcomes as measured by clinician 
evaluation of the lesions by photographs.  It should be noted that this study had a very short follow-
up period of 2 months, significantly limiting evaluation and interpretation of the efficacy of the 
antimicrobial regimen.   
5.2.3 Epiroprim (Hoffmann-La Roche Ltd) 
 
M. ulcerans is susceptible to epiroprim in vitro, with MIC values ranging between 0.5 and 1.0 mg/ml.  
Epiroprim was shown to be the most potent among the dihydrofolate reductase inhibitors studied.  
Of note, synergistic activity was seen when epiroprim was used in combination with dapsone [26].  
Epiroprim has been shown to have in vivo activity against M. leprae [71], but there are no data publicly 
available examining the drug’s in vivo activity against M. ulcerans.  This drug was originally developed 
by Hoffmann-La Roche Ltd (Basel, Switzerland) but it is not clear whether its development has been 
discontinued [72].  However, there has recently been renewed interest in the anti-mycobacterial 
activity of dihydrofolate reductase inhibitors [73], and compounds belonging to this class may have a 
role in Buruli ulcer treatment. 
5.2.4 Diarylquinoline TMC207 (Johnson & Johnson) 
 
TMC207 (bedaquiline) is a member of a new class of anti-mycobacterial agents called 
diarylquinolines that act by inhibiting mycobacterial ATP synthase and leading to ATP depletion and 
pH imbalance [74].  This drug has a broad spectrum of activity against several mycobacteria, 
including M. tuberculosis, M. bovis, M. avium, M. kansasii, M. smegmatis and M. ulcerans [75]. 
 
TMC207 has potent bactericidal activity in the established murine TB infection model.  
Pharmacokinetic and pharmacodynamic studies in mice demonstrated a long half-life in plasma and 
tissue and high tissue penetration. These are all attributes that are valuable for the treatment of 
chronic infections and also may be important for the development of simplified dosing regimens 
[75].  In phase II trials, TMC207 was shown to be safe and well-tolerated [76].  Of note, TMC207 
was recently approved by the United States’ Food and Drug Administration (FDA) for the treatment 
of multi-drug resistant TB (MDR-TB) and is undergoing review by the European Medicines Agency 
(EMA) [77].   
 
Furthermore, in vitro studies have showed that TMC207 has remarkable activity against M. ulcerans 
(MIC50=0.03 mg/ml) [34].  In experiments using the mouse footpad curative model, TMC207 
monotherapy demonstrated bactericidal activity comparable to that of moxifloxacin but lower than 
the bactericidal activity of rifampicin or the aminoglycosides [34].  When combination regimens 
were tested, treatment with rifampicin-TMC207 had comparable results to rifampicin-streptomycin 
with respect to the mean number of CFU per footpad and the proportions of mice with culture-
positive footpads at 4 and 8 weeks of treatment.  However, because the mean CFU and the 
proportion of culture-positive footpads among the mice administered rifampicin-TMC207 did not 
differ significantly from the results among mice treated with rifampicin monotherapy, Ji and 
collaborators concluded that the bactericidal activity of the rifampicin-TMC207 combination was 
mainly attributable to rifampicin.  Nevertheless the use of drugs in combination would likely be 
essential in order to prevent selection of rifamycin resistance.  The in vitro activity of TMC207 
suggests that it should be further explored in combination possibly with other antibiotics in the 
treatment of Buruli ulcer disease.  Indeed, drug interaction studies in patients showed that 
administration of rifampicin in combination with TMC207 causes a 50% decrease in TMC207 serum 
level, which could easily interfere with the efficacy of the rifampicin-TMC207 combination [78]. 
Thus, there may be other antibiotics that could demonstrate potentially greater anti-mycobacterial 
activity when co-administered with TMC207 than the rifampicin-aminoglycoside regimen currently 
recommended. 
 
5.3 Antibiotics of unclear value due to lack of sufficient amount of data 
 
Of the remaining antibiotics with anti-mycobacterial activity, two oral drugs – amoxicillin-
clavulanate and co-trimoxazole – are potentially viable options for treatment of Buruli ulcer disease 
but data are lacking regarding their effectiveness against M. ulcerans.  In addition, many of the new 
anti-tuberculosis drugs coming down the drug development pipeline have limited or no data 
available regarding their complete spectrums of anti-mycobacterial activity. 
 
5.3.1 Amoxicillin-clavulanate and Co-trimoxazole 
 
Amoxicillin-clavulanate is well tolerated, safe for pediatric patients and pregnant women, and 
inexpensive.  Furthermore, it has been shown to have in vitro activity against various mycobacterial 
species including M. tuberculosis, M. kansasii and M. marinum [79,80].  However, there is no data on 
whether amoxicillin-clavulanate has in vitro activity against M. ulcerans.  A potential caveat is that a 
case report has been published previously on the lack of improvement in Buruli ulcer disease in one 
patient treated with amoxicillin-clavulanate [45].  Co-trimoxazole, on the other hand, has been 
shown to have in vitro activity against M. ulcerans, but did not appear to have any benefit in treating 
Buruli ulcer disease in a small clinical study [17].  Further investigation into the potential clinical 
utility of co-trimoxazole is warranted given that this previous study was small, with only 12 patients 
who had significant variation in disease presentation.  Co-trimoxazole is attractive as an oral agent 
that is well tolerated and can be used safely in pediatric patients. 
 
5.3.2 Nitro-dihydro-imidazooxazole OPC-67683 (Otsuka Pharmaceuticals, Japan) 
 
OPC-67683 (delamanid) is a new nitroimidazole derivative currently in development.  Proposed 
mechanisms of action for the nitroimidazoles include the inhibition of essential mycobacterial cell 
wall components as well as intracellular nitric oxide release.  Phase I and Phase IIa clinical trials 
demonstrated that this compound has a good safety and tolerability profile.  Possible drug 
interactions with rifampicin and pyrazinamide have emerged and need to be further clarified.   
OPC-67683 was found to be active also against M. kansasii [81], suggesting that it can be active 
against other members of the genus Mycobacterium, including M. ulcerans.  Although OPC-67683 is 
closely related to PA-824 – another nitroimidazole that does not have in vitro or in vivo activity against 
M. ulcerans [34] – the two chemical entities do not belong to the same subclass of molecules, 
suggesting that it might be worth independently investigating whether OPC-67682 is active against 
M. ulcerans. 
5.3.3 Oxazolidinones:  PNU-100480 (Pfizer) and AZD-5847 (AstraZeneca) 
 
New drugs have been developed in the class of oxazolidinones, which act as protein synthesis 
inhibitors and boasts linezolid as a member.  Linezolid has demonstrated activity against M. ulcerans 
in vitro and in vivo; in addition, the bactericidal activity of the rifampicin-linezolid regimen was shown 
to be similar to that of the rifampicin-moxifloxacin and rifampicin-TMC207 regimens in the mouse 
curative model [34].  Laboratory-based studies suggest that the new oxazolidinones may be as active 
as linezolid against M. tuberculosis but with fewer associated toxicities [82-84].  An initial clinical study 
aimed at evaluating the safety, tolerability and pharmacokinetic profile of PNU-10048 administered 
at different dosages (100, 300, 600 mg twice a day or 1200 mg once a day) found that all doses were 
safe and well-tolerated [85].  Data is pending from a recently completed, phase II study testing the 
early bactericidal activity (EBA) of 600 mg and 1200 mg daily doses for 14 days [86]. 
 
The AZD-5847 compound developed by AstraZeneca has a MIC similar to that of linezolid and 
PNU-10048 and has been showed to be active against M. tuberculosis both in vitro and in animal 
models [84].  AZD-5847 is currently undergoing phase II studies [87].  It is postulated that 
antimicrobial resistance to the oxazolidinones may be less frequent due to the need for mutations in 
the 23S ribosomal RNA subunit [84]. 
 
5.3.4 Benzothiazinone BTZ043 (NM4TB/AstraZeneca) 
 
BTZ043 belongs to a new class of antimycobacterial agents called benzothiazinones whose major 
target is an enzyme (decaprenylphosphoryl-b-D-ribose 2’ epimarase) involved in the synthesis of the 
cell wall component arabinans [88].  BTZ043 has been tested and shown to have in vitro activity 
against M. tuberculosis (including MDR- and extremely drug resistant-TB clinical isolates), M. smegmatis 
and M. bovis [88,89].  The drug’s bactericidal activity is comparable to isoniazid when tested in vitro 
against exponentially growing M.tuberculosis culture, but less effective when tested in model systems 
(auxotrophy and starvation) involving metabolically inert M. tuberculosis [88].  It is worth noting that 
the enzyme targeted by BTZ043 (DprE1) is highly conserved in orthologous genes from various 
actinobacteria.  The M. ulcerans protein YP908322.1 (NCBI reference sequence) shares 87% 
sequence identity with the M. tuberculosis Rv3790 protein, and the Cys amino-acid residue conferring 
sensitivity to BTZ043 is conserved.  Based on these data, BTZ043 could have significant activity 
against M. ulcerans and should be further studied. 
5.3.5 Diamine SQ-109 (Sequella Inc.) 
 
SQ-109 is a novel 1,2-ethylenediamine-based ethambutol analog.  Although it targets cell wall 
formation like ethambutol, SQ-109 acts on a different target – the transmembrane transporter 
encoded by mmpL3 gene – and thus has no cross-resistance with ethambutol [90].  A phase 2a early 
bactericidal activity study is underway to determine safety, sputum clearance, and pharmacokinetics 
of SQ-109 alone or with rifampicin in patients with smear-positive pulmonary tuberculosis [91].  
The gene encoding the M. tuberculosis membrane transport protein MmpL3 (Rv0206c) is conserved 
across all mycobacteria for which genome sequences are available and the M. ulcerans protein 
YP_905156.1 (NCBI reference sequence) shares 74% identity with the M. tuberculosis MmpL3 protein. 
This suggests that SQ-109 might be active against M. ulcerans and further testing should be pursued. 
 
5.4 Antibiotics that are not suitable for the treatment of Buruli ulcer 
 
Several drugs with activity against other mycobacterial species have been determined to be 
unsuitable for the treatment of Buruli ulcer disease (see Appendix Table A.4), primarily taking into 
account the challenges associated with their use in resource-limited settings. The main criteria 
applied for discarding the drugs listed in the table were the following: 
 lack of evidence of drug activity against M. ulcerans 
 administration route or storage conditions not ideal (i.e. injectable or refrigeration required) 
 contraindicated for use in pediatric patients 
 major side effects or toxicities 
 expensive 
It is also worth noting that one of the new anti-tuberculosis drugs being developed, PA-824, has 
been shown to lack in vitro activity against M. ulcerans [34].  Developed by PathoGenesis-Chiron and 
currently being promoted by the TB Alliance, PA-824 is a nitroimidazole derivative like OPC-67683 
that has bactericidal activity in vitro against both replicating and non-replicating M. tuberculosis [92]. 
 
When tested specifically against M. ulcerans, PA-824 had very high MIC values (16 mg/ml) in vitro, 
and studies in the mouse footpad curative model confirmed its lack of activity against M. ulcerans [34]. 
Post-treatment mean CFU values in mice administered PA-824 did not differ significantly from pre-
treatment values.  Thus, PA-824 does not appear to have application for Buruli ulcer treatment; 
however, given the potent bactericidal activity of this drug against tuberculosis, researchers are 
identifying novel nitroimidazole derivatives that could potentially have activity against M. ulcerans in 
addition to M. tuberculosis. 
 
 
6. TOWARD IDENTIFYING NEW BURULI ULCER CHEMOTHERAPEUTICS 
 
Although promising alternatives have been identified to the currently recommended rifampicin and 
streptomycin regimen for Buruli ulcer treatment, major knowledge gaps remain that prevent 
rigorous conclusions from being drawn with respect to all of the existing and upcoming drugs with 
anti-mycobacterial activity.  In addition, while the rifampicin and clarithromycin combination may 
prove to be an effective all-oral regimen that is not inferior to the currently recommended treatment 
approach, it does not fully meet the criteria for end-user requirements outlined in the introduction 
(see Table 2.1).  Notably, this treatment regimen can pose challenges for the treatment of Buruli 
ulcer disease in patients co-infected with TB and HIV due to drug-drug interactions with 
antiretrovirals.  Thus, there is a critical need to strengthen and expand research efforts in the 
development of effective chemotherapeutic approaches for Buruli ulcer disease that can be 
successfully implemented in the resource-poor settings where this disease is endemic. 
 
With the goal of resolving deficiencies in our understanding of the antimicrobial susceptibility 
profile of M. ulcerans as well as promoting the potential use of existing or newly developed drugs for 
Buruli ulcer disease, we herein propose a research agenda outlining short-term and long-term 
objectives that should be addressed. 
 
6.1 Short-term objective:  Systematically identify all existing, orally administered drugs with 
activity against M. ulcerans and their relative potencies 
 
Chemotherapy treatment for Buruli ulcer with rifampicin-streptomycin has already had clinical 
success, but this regimen presents some major disadvantages, especially when considered for use in 
Buruli ulcer-endemic regions.  Indeed, administration through intramuscular injection and the long-
term toxicities associated with aminoglycosides complicate the delivery of Buruli ulcer care in less-
developed countries.  With the aim of identifying alternative, orally administered regimens, the 
mycobacterial activity of several existing and newly developed drugs as monotherapy or in 
combination has been investigated in animal models [15,23,25,29,32-34].  These studies have offered 
promising results about possible alternative regimens, some of which have been studied in clinical 
trials or empirically tried in patients with success.  However, the data are fragmented without a 
clearly defined research agenda, which has made it difficult to draw robust conclusions.  
Systematically studying drugs, drug candidates and combination regimens in murine models under 
the same experimental conditions with appropriate follow-up evaluation to exclude disease relapse 
would enable us to thoroughly assess the sterilizing activity of different regimens and more 
accurately determine their potential efficacy as Buruli ulcer chemotherapeutics.  Based on these 
rigorous experimental models, future clinical trials could be undertaken to establish clinical 
effectiveness. 
 
Studies comparing the anti-mycobacterial activities of rifampicin, aminoglycosides and other orally 
administered drugs in animal curative models have demonstrated that: i) rifampicin and 
aminoglycosides have clear bactericidal activity; and ii) clarithromycin, moxifloxacin, linezolid and 
TMC207 also have bactericidal activity but are less potent than rifampicin and the aminoglycosides 
[33,34].  In combination regimens with these drugs, most of the bactericidal activity was attributable 
to rifampicin; however, combination therapy remains preferred over rifampicin monotherapy to 
prevent the development of rifampicin resistance to M. ulcerans.  Comparable cure rates to that of the 
rifampicin-aminoglycoside combination were seen after 8 weeks of treatment with these alternative 
regimens.  Whether the sterilizing activity of these alternative regimens in clinical studies is 
equivalent or potentially superior to the currently recommended antibiotic regimen remains to be 
fully answered. 
 
As an oral antibiotic, clarithromycin is an attractive alternative to the aminoglycosides currently 
recommended for Buruli ulcer treatment.  Clinical studies have already indicated that a fully oral 
regimen can successfully treat early stage, limited disease.  Recent clinical studies have shown that 
partial or complete treatment with rifampicin-clarithromcyin may be equivalent to standard 
chemotherapy with rifampicin-streptomycin [40,51].  In addition, this oral regimen has been shown 
to be used successfully in more vulnerable populations such as pregnant patients [49].  Taken 
together, these data expand on earlier pilot studies to demonstrate that Buruli ulcer disease can be 
effectively treated with antibiotics; and importantly, early-stage, limited lesions may not even require 
additional surgery. Building on this work, the WHO is sponsoring a randomized multicenter trial 
aimed at establishing that 8 weeks of rifampicin-clarithromycin will be equivalent to the current 
standard of care. 
 
While establishing the clinical efficacy of rifampicin-clarithromycin would represent a valuable step 
forward, there remains an urgent need to identify additional alternative chemotherapeutics.  This 
oral combination, like the current standard of care, has significant limitations that threaten its wide-
scale implementation.  Drug-drug interactions between antiretrovirals and both rifampicin and 
clarithromycin will complicate the use of this regimen in people co-infected with HIV.  Both drugs 
interfere with the CYP3A enzymatic pathway, thereby affecting serum levels of antiretrovirals with 
unclear clinical impact [93,94].  In addition, only a liquid-based formulation of clarithromycin is 
available for pediatric patients, which would be challenging to administer and store in rural 
community settings. Clarithromycin’s twice a day dosing schedule would likely lower patient 
adherence to treatment. 
 
The use of azithromycin, a once-daily macrolide closely related to clarithromycin, could alleviate 
some of the aforementioned concerns.  In addition, it could provide an alternative oral option for 
patients who do not tolerate clarithromycin.  However, there is very little data on the use of 
azithromycin against M. ulcerans.  Azithromycin does appear to have weaker bacteriostatic activity in 
vivo than clarithromycin, but comparable to that of fluoroquinolones.  The published success with 
clinical use of fluoroquinolones and clarithromycin against Buruli ulcer, along with the routine use of 
azithromycin for M. avium complex infections, strongly supports the potential application of 
azithromycin in treating M. ulcerans.  Further investigation is needed to better define the possible role 
of azithromycin – first pursuing in vivo studies using the mouse footpad model and subsequently 
conducting clinical trials.  
 
Fluoroquinolones represent another class of drugs with significant potential as an oral 
chemotherapeutic option for Buruli ulcer disease.  Several generations of fluoroquinolones have 
been developed and are currently in clinical use, including the second-generation ciprofloxacin and 
third-generation moxifloxacin and levofloxacin.  Most of the available laboratory and clinical data 
have focused on ciprofloxacin and moxifloxacin, but it is expected that levofloxacin would have 
comparable activity against M. ulcerans.  The later generation fluoroquinolones are preferred over 
ciprofloxacin because of better safety, tolerability and convenience of use with once daily dosing.  It 
should be noted that sitafloxacin, a fourth-generation drug, was shown to have more potent in vitro 
activity against M. ulcerans when compared to the others.  However, given the drug’s increased 
likelihood of phototoxicity in Caucasian populations and limited market availability, it would not be 
pragmatic to focus on this agent over the third-generation drugs.  
 
Fluoroquinoles boast several features that make them attractive for Buruli ulcer treatment: excellent 
spectrum of activity, good tissue penetration and oral route of administration.  In addition, there are 
no major drug-drug interactions between fluoroquinolones and antiretroviral drugs, suggesting a 
potential role for fluoroquinolone use in patients co-infected with HIV and mycobacterial infections.  
The major disadvantage of this class is the concern for fluoroquinolone-induced joint or cartilage 
toxicity in pediatric patients based on juvenile animal studies [95,96].  However, data on the safety of 
fluoroquinolones in children is certainly limited. The exact frequency of side effects related to 
fluoroquinolone use in children is difficult to estimate because of the paucity of prospective studies. 
Furthermore, fluoroquinolones – specifically ciprofloxacin – are often used in children in off-label 
circumstances and associated adverse events are rarely published [97,98].  Available data about 
pediatric tolerance of fluoroquinolones come principally from two retrospective studies and one 
prospective observational study [99-101].  Each of these studies had a large sample size and found a 
low rate of articular adverse events (0-3.8%); in addition, all adverse events were minor without 
significant sequelae.  Thus, much of the data has failed to detect an increased rate of articular side 
effects in children treated with fluoroquinolones.  Despite these encouraging results, it is still 
recommended that fluoroquinolones be used with reservation in children and only as second-line 
agents, primarily in cases where all other previous treatments have failed or for the treatment of life-
threatening infections where the use of fluoroquinolones has been showed to be of advantage (i.e. 
cystic fibrosis, typhoid fever, severe shigella dysenteries, enterobacterial meningitis).  
 
Other antibiotics, specifically dapsone, amoxicillin-clavulanate and co-trimoxazole, should also 
receive consideration for their possible role in Buruli ulcer treatment.  These drugs meet many of the 
end-user requirements outlined early on, including oral administration, safe for pediatric and 
possibly pregnant patients, and minimal drug-drug interactions with ARVs.  However, their weaker 
activity in vitro against mycobacterial species including M. ulcerans leads us to prioritize them lower 
than the macrolides and fluoroquinolones 
 
In order to draw rigorous conclusions regarding the utility of existing oral drugs for Buruli ulcer 
chemotherapy and ensure that their potential value is thoroughly assessed, the anti-mycobacterial 
activity of the drugs described in Table 6.1 should be established under standardized experimental 
conditions in both in vitro and in vivo models.   
 
 
Table 6.1 – Antibiotics that deserves further systematic investigation 
 
Drug Rationale for Strong Consideration 
Azithromycin  In vivo studies of azithromycin indicate it has bacteriostatic activity 
against M. ulcerans, comparable to that of moxifloxacin.  
 Successful use of clarithromycin and moxifloxacin clinically supports a 
potential role for azithromycin 
 Possible use in paediatric and pregnant patients (pregnancy category B) 
  Limited drug-drug interactions with ARVs and no dose adjustment 
required 
 Cheaper than clarithromycin and more convenient administration with 
once daily dosing 
Fluoroquinolones  Reported drug-drug interactions with ARVs limited to didanosine 
 Good safety and tolerability profile 
 Convenient administration with once daily dosing schedule 
 Rationale for Consideration 
Dapsone  Safe for pediatric patients 
 No significant interactions with ARVs 
Amoxicillin-
Clavulanate 
 Pregnancy category B 
 Safe for pediatric patients 
 No interaction with ARVs 
 
Co-trimoxazole 
 Drug-drug interaction with ARVs have been reported (primarily with 
lamivudine, ritonavir, indinavir and delavirdine) but no dose adjustment is 
recommended 
 Safe for paediatric patients  > 2 years old 
 
By systematically testing these drugs under the same laboratory conditions, the relative anti-
mycobacterial activity of each drug can be more clearly delineated and can inform which drugs and 
in what order they should be pursued in clinical trials.  To some extent, this information is available 
with respect to the various generations of fluoroquinolones, with sitafloxacin having greater potency 
over moxifloxacin or levofloxacin.  However, in addition to the relative anti-mycobacterial potency, 
the safety profile and dosing characteristics should be taken into consideration when deciding which 
drugs to study first.  The phototoxicity associated with sitafloxacin and the drug’s limited market 
availability make this drug a less pragmatic consideration at this time.  With this in mind, we propose 
that top priority be assigned to investigating azithromycin and the fluoroquinolones moxifloxacin 
and levofloxacin for Buruli ulcer treatment. 
6.2 Short-term objective:  Identify an orally administered combination regimen for Buruli 
ulcer disease using existing drugs 
 
Once a pool of orally administered drugs with activity against M. ulcerans has been identified, an 
important next step will be to identify the combination regimen with the greatest bactericidal 
potency in animal models.  For example, several observational studies and case series have 
demonstrated the clinical efficacy of fluoroquinolones, primarily ciprofloxacin and moxifloxacin, in 
conjunction with rifampicin in treating Buruli ulcers [50,53,102,103].  Due to the varying durations 
of treatment, measures of disease response, and methods of follow-up presented in these studies, it 
is difficult to directly compare the efficacy of fluoroquinolone-containing regimens to the current 
standard of care.  Thus, the relative efficacy of the following regimens under the same laboratory 
conditions and clinical settings should be studied: rifampicin-streptomycin, rifampicin-
clarithromycin, rifampicin-azithromycin and rifampicin-fluoroquinolone.  In comparing these 
regimens, the levels of bactericidal activity after 8 weeks of treatment, time to culture-sterilization, 
and relapse/recurrence rates during post-treatment follow-up should be assessed.  Subsequently, 
clinical trials similar to the one being conducted by the WHO studying rifampicin-clarithromycin 
should be pursued using other combination regimens. 
 
If in vitro and in vivo studies show a significant MIC for amoxicillin-clavulanate and co-trimoxazole, 
further studies examining the activity of these drugs in combination with rifampicin also should be 
pursued.  Rifampicin-dapsone has been studied previously in a clinical trial but the small sample size 
and short duration of follow-up prevent any solid conclusions being drawn.  Further investigation of 
this dual regimen with better-designed study protocols is likely warranted given dapsone’s safety and 
tolerability profile. 
 
Another unanswered question is whether combination regimens with other rifamycins, such as 
rifapentine and rifabutin, should be explored more systematically.  Mouse model studies have shown 
that rifapentine may have superior anti-mycobacterial activity compared to rifampicin, and 
rifapentine’s longer half-life may allow for intermittent dosing.  However, a phase II clinical trial 
comparing the 2-month culture conversation rate of the standard, first-line tuberculosis regimen 
(RIF-INH-EMB-PZA) to the same regimen with rifapentine instead of rifampicin failed to show 
superior activity for the rifapentine-containing regimen [104].  Several studies are in progress to 
determine whether rifapentine can be used to optimize and shorten the duration of TB treatment.  
The results of these studies may offer important lessons to guide future research on the use of 
rifapentine in the treatment of Buruli ulcer disease. 
 
6.3 Short-term objective:  Explore the use of multi-drug combination therapy to shorten 
treatment duration 
 
Given the challenges of successfully completing 8 weeks of antibiotics in many of the rural 
community settings where Buruli ulcer is endemic, there is a need for identifying regimens that could 
shorten the duration of treatment.  Combining multiple drugs with different mechanisms of action 
may be one approach toward this aim.  Despite the successful use of quadruple drug regimens for 
tuberculosis, there is little data on the use of multi-drugs regimens for Buruli ulcer beyond a few 
published case reports.  Thus, further research is needed to assess whether multi-drug regimens 
could result in significantly increased levels of bactericidal activity so as to shorten time to culture 
sterilization and cure. 
 
Very little is known about whether M. ulcerans develops antimicrobial resistance similar to what is 
seen with M. tuberculosis.  The development of drug resistance has been documented in vitro, 
suggesting that this is likely to become an important concern with increased antibiotic use [16].  The 
potential for antimicrobial drug resistance would be another reason for considering multi-drug 
combinations for Buruli ulcer treatment.  Of note, the triple combination of rifampicin-
clarithromycin-sparfloxacin was tested in animal models and found to have lower anti-mycobacterial 
activity when compared to the combination rifampicin-aminoglycoside [24].  It is well known that 
fluoroquinolones and clarithromycin have weaker activity against M. ulcerans when compared to 
aminoglycosides, which may account for the results seen. However, no direct comparison was made 
between the activity of the triple regimen and the activities of rifampicin-clarithromycin or 
rifampicin-fluoroquinolone.  Thus, we have no data available assessing whether multi-drug 
combinations have added value compared to dual drug regimens, either in improving clinical efficacy 
or preventing drug resistance. 
 
Inclusion criteria for selecting drugs to test in multi-drug regimens should focus on targeting 
different biological pathways of the bacteria and capitalizing on synergistic drug-drug interactions.  
Animal studies could help define the most active combinations that should then be considered for 
further clinical studies.  Based on existing data, the regimen of rifampicin, a macrolide and 
fluoroquinolone may be worth pursuing further in clinical studies.  The other drugs described in 
Section 6.2 are unlikely to have sufficient individual bactericidal activity to warrant their investigation 
in multi-drug regimens.   
 
There are disadvantages to multi-drug regimens that should be mentioned.  Increasing the number 
of drugs in a regimen raises the risk of additional toxicities and complicates drug administration with 
more pills to be taken.  Substantially shortening the duration of antibiotic therapy would be a 
necessary condition to warrant the increased risks and hassles associated with a multi-drug regimen.  
Moreover, very recent data suggests that stronger bactericidal activity does not necessarily translate 
into more effective sterilizing activity.  Almeida and colleagues found that although treatment with 
daily rifapentine was more bactericidal than daily rifampicin (both in conjunction with streptomycin), 
the relapse rate and time to relapse after stopping treatment were not different between the two 
groups [105].  Interestingly, the authors suggest that treatment of Buruli ulcer is more dependent on 
reversal or inhibition of mycolactone-induced local immunodeficiency by the treatment, as opposed 
to the bactericidal activity of the drugs.  Thus, specifically targeting the inactivation of mycolactone 
or inhibition of its immunosuppressive activity may represent a complementary or more efficacious 
approach to improve and shorten the duration of Buruli ulcer chemotherapy.  
 
6.4 Short-term objective: Establish the role of and timing for surgical intervention in Buruli 
ulcer treatment 
 
Finally, the increasing role of antimicrobials in Buruli ulcer treatment does not exclude the potential 
value of surgical interventions in specific cases.  While antimicrobial therapy has been shown to 
effectively heal small, early-stage lesions and reduce the size of larger lesions so as to allow for less 
extensive surgery, the exact role and timing for surgical interventions in conjunction with Buruli 
ulcer chemotherapy are not well defined.  To that end, a randomized, parallel-assignment clinical 
trial is underway exploring the impact of delayed surgery on treatment outcomes in Buruli ulcer 
patients receiving rifampicin-streptomycin [106].  Defining the appropriate criteria for surgical 
intervention to optimize treatment outcomes will help ensure that limited resources in endemic 
regions are maximally used.   
 
A summary of recommended short-term research aims is presented in Table 6.4. 
 
 
Table 6.4 – Short-term research aims proposed to guide the identification of new Buruli ulcer 
chemotherapeutics. 
 
IN VITRO STUDIES IN VIVO STUDIES CLINICAL STUDIES 
TOP PRIORITY: 
 Compare the anti-mycobacterial 
activity of single drugs and the 
additive or synergistic effect of 
drug combinations under 
standardized experimental 
conditions. Drugs and drug 
combinations to consider: 
o Clarithromycin 
o Azithromycin 
o Fluoroquinolones 
(moxifloxacin, levofloxacin) 
o Rifampicin-Clarithromycin 
o Rifampicin-Azithromycin 
o Rifampicin-Fluoroquinolone 
 Assess and compare anti-
mycobacterial activity under 
standardized experimental 
conditions of combination 
regimens: 
o Rifampicin-Clarithromycin 
o Rifampicin-Azithromycin 
o Rifampicin-
Fluoroquinolone 
 
 Clinical trials to assess all-oral 
regimens that can offer an 
alternative to rifampicin-
clarithromycin, such as 
rifampicin-moxifloxacin or 
rifampicin-azithromycin (if 
animal studies are promising). 
 
 Clinical trial to study early 
versus delayed surgical 
intervention in conjunction 
with antibiotic therapy 
MEDIUM PRIORITY: 
 Compare the anti-mycobacterial 
activity of single drugs and the 
additive or synergistic effect of 
drug combinations under 
standardized experimental 
conditions of the following 
compounds: 
o Dapsone 
o Amoxicillin-clavulanate 
o Co-trimoxazole 
o Rifampicin-Dapsone 
o Rifampicin-Amoxicillin-
clavulanate 
o Rifampicin-Co-trimoxazole 
 Consider pursuing in vivo studies 
of dapsone, amoxicillin-
clavulanate or co-trimoxazole if 
in vitro studies are promising for 
these drugs 
 
 Consider assessing the activity 
of rifapentine-based regimens in 
vivo based on results of ongoing 
studies of tuberculosis 
treatment  
 
LOW PRIORITY 
  Consider pursuing in vivo studies 
of multi-drug regimens (i.e. 
rifampicin-macrolide-
fluoroquinolone) and assess 
their potential to shorten 
treatment duration 
 
 
6.5 Long-term objective: Explore the use of new drugs for Buruli ulcer treatment 
 
Importantly, there have been significant advances in the development of novel anti-tuberculosis 
drug candidates in recent years.  Given the highly conserved sequences between mycobacterial 
species, some of these drug candidates may have clinically important activity against M. ulcerans and 
should be investigated further.  In addition, new drug candidates against TB are being pursued that 
have fewer drug-drug interactions with antiretrovirals, are orally administered and can be produced 
in fixed-dose combinations, all of which are end-user requirements for Buruli ulcer 
chemotherapeutics (see Table 2.2).  Drug candidates coming down the pipeline for anti-tuberculosis 
treatment thus should be evaluated for potential in vitro and in vivo activity against M. ulcerans.  For 
example, the diarylquinolone TMC207 was shown to have in vitro activity against M. ulcerans while the 
nitroimidazole PA-824 did not have any such activity [34].  Furthermore, Ji and colleagues found 
that treatment with the combination regimens rifampicin-TMC207, as well as rifampicin-
moxifloxacin and rifampicin-linezolid, had comparable bactericidal effects to rifampicin-
aminoglycoside in animal models, suggesting these may be viable orally administered options that 
should be further investigated.  Other attractive options include the use of PNU10048 and 
AZD5847 – new oxazolidinones that may have similar spectrums of activity to linezolid, which has 
demonstrated activity against M. ulcerans.  However, the growing multi-drug resistant tuberculosis 
epidemic demands a cautious approach, prioritizing the use of these agents for MDR-TB so as to 
protect against the selection of additional drug resistance.   
 
Antimicrobial resistance is of particular concern because Buruli ulcer disease is endemic to areas 
where tuberculosis is highly prevalent.  Although screening for active tuberculosis is recommended 
prior to initiating Buruli ulcer disease, current limitations to accurately diagnosing active disease 
prevent reliance on this screening strategy.  While new drugs with proven efficacy against TB should 
be restricted in a responsible public health approach, the research and development process offer 
other chemical entities and classes of compounds with possible anti-mycobacterial activity.  Drugs 
that are discarded in the process for lack of anti-tuberculosis activity, for example, could be further 
investigated for activity against M. ulcerans.  In addition, classes of anti-microbials or anti-infectives 
with broad spectrum of activity could represent additional sources of compounds active against M. 
ulcerans with no or limited cross-activity against M. tuberculosis 
.   
In considering the application of anti-tuberculosis drugs for Buruli ulcer treatment, it will be critical 
to better understand the epidemiology of Buruli ulcer disease since it is endemic to regions where 
tuberculosis is highly prevalent.  Specifically, studies must be conducted to address whether, during 
Buruli ulcer treatment, there could be the potential to inadvertently treat active tuberculosis with 
only one or two drugs and the implications of this on the development of resistant M. tuberculosis 
strains.  Further guidelines are needed to determine how to optimally treat both diseases while 
reserving the most potent anti-tuberculosis drugs for the management of tuberculosis, which has 
much more profound morbidity and mortality associated with it. 
 
In the absence of epidemiological data on co-existing mycobacterial infections, there is an important 
caveat that arises with respect to the clinical application of rifampicin-clarithromycin.  
Clarithromycin and its counterpart azithromycin lack anti-tuberculosis activity.  The use of a 
rifampicin-macrolide regimen in a patient with undiagnosed active tuberculosis could lead to 
rifampicin monotherapy and raise the risk of developing rifampicin resistance.  While aggressive 
screening for tuberculosis at the initiation of and during treatment for Buruli ulcer disease would 
mitigate the potential risk, this is a major hurdle for implementation of rifampicin-clarithromycin 
beyond the closely-monitored environment of clinical studies.  Ideal solutions to address this include 
the identification of better diagnostic tests to definitely exclude tuberculosis co-infection or 
alternatively he development of new chemotherapeutic regimens that are rifampicin-free and do not 
include any of the 1st or 2nd line agents recommended for the treatment of tuberculosis.  Taking into 
consideration that rifampicin is the most potent oral drug with activity against M. ulcerans thus far 
identified, a more pragmatic short-term solution is represented by the prioritization of combination 
regimens with at least two anti-tuberculosis agents.  
 
Lastly, the dihydrofalate reductase inhibitors are another class of drugs that deserve future 
investigation given that M. ulcerans has demonstrated susceptibility in vitro.  Of note, synergistic 
activity was seen when the dihydrofolate reductase inhibitor epiroprim was used in conjunction with 
dapsone.  There have been no studies of epiroprim activity in vivo against M. ulcerans, and this should 
be pursued.  Furthermore, dual and triple combinations of epiroprim, dapsone and rifamycins 
should be studied in vitro and in vivo under standardized conditions. 
 
Identifying the full anti-mycobacterial activity profiles of newly developed drugs, establishing their 
safety and tolerability, and developing guidelines for the responsible use of these drugs will be 
critical components of the Buruli ulcer research and public health agenda. 
 
 
7. CONCLUSIONS 
 
This is an exciting time for Buruli ulcer research and public health programs.  With the 
implementation of effective Buruli ulcer chemotherapy, there has been a transformation in how this 
disease can be treated.  While major challenges persist in scaling up treatment programs due to the 
resource constraints in Buruli ulcer-endemic areas, there is considerable research exploring the 
potential use of alternative drugs currently in existence or being newly developed.  However, these 
data are sporadic and incomplete.  Recent clinical trials sponsored by the WHO are systematically 
attempting to realize a fully oral treatment regimen, which will be a valuable step forward.  We have 
outlined further steps that can be undertaken to systematically identify and establish alternative 
chemotherapeutics.  These new regimens may come even closer to meeting the end-user 
requirements that we believe are essential for devising the most effective and readily implementable 
treatment programs for Buruli ulcer disease.  With continued research and public health 
commitment, this goal may be soon within our grasp. 
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APPENDIX 
 
Table A.1 – Search strategy for identification of articles for inclusion 
 
Database Search Terms and Strategy 
PubMed ((((“Therapeutics” [Mesh] OR (therapy OR treatment OR intervention)) AND (((“buruli ulcer” [MeSH 
Terms] OR (“buruli”[All Fields] AND “ulcer[All Fields]) OR “buruli ulcer”[All Fields})) OR 
(mycobacterium ulcerans)) 
EMBASE ((buruli AND (“ulcer”/exp OR ulcer) or (“mycobacterium”/exp OR mycobacterium AND ulcerans)) 
AND (therapy or treatment or intervention or therapeutics)) 
Scopus ((“mycobacterium ulcerans” or “Buruli ulcer”) AND (therapy OR treatment OR intervention)) 
WHO Global Health Library “mycobacterium ulcerans” OR “Buruli ulcer” 
CAB Abstracts exp Buruli ulcer/ or Mycobacterium ulcerans.od. 
Cochrane Library (MeSH descriptor:  [Mycobacterium ulcerans] OR “mycobacterium ulcerans”) 
 
Table A.2 – Drugs with known anti-mycobacterial activity 
Drugs to treat: Group 1 – First-line 
agents 
Group 2 – Second-line 
agents 
Group 3 – Third-line 
agents (unclear efficacy) 
Group 4 – New drugs in 
development 
M. tuberculosis   Isoniazid (INH) 
 Rifampicin (RIF) 
 Ethambutol (EMB) 
 Pyrazinamide (PZA) 
 Other rifamycins: 
Rifapentine (RFP), 
Rifabutin (RFB), 
Rifalazil  
 Aminoglycosides 
(injectables): Streptomycin 
(STR), Kanamycin (KAN), 
Amikacin (AMK), 
Capreomycin (Cm), 
Viomycin (Vi) 
 Fluoroquinolones (oral): 
Ciprofloxacin (CIP), 
Ofloxacin (OFX), 
Levofloxacin (LVX), 
Moxifloxacin (MXF), 
Gatifloxacin (GFX) 
 Other oral drugs with 
bacteriostatic activity: 
Ethionamide (Eto), 
Protionamide (Pto), 
Cycloserine (Cs), 
Terizidone (Trd),  
P-aminosalicylic acid 
(PAS), Thiacetazone (Th) 
 Clofazimine (CFZ) 
 Amoxicillin/Clavulanate 
(AMC) 
 Clarithromycin (CLR) 
 Linezolid (LZD) 
 Meropenem-clavulanate 
(activity against MDR-TB) 
 TMC207 (bedaquiline) 
 PA-824 
 OPC-67683 
 PNU-100480 
 AZD-5847 
 BTZ043 
 SQ-109 
M. leprae   Rifampicin 
 Dapsone (DDS) 
 Clofazimine 
  Epiroprim 
 
 
M. avium complex   Clarithromycin   Telithromycin (TEL)   
 Azithromycin (AZM) 
 Ethambutol  
 Rifabutin  
 Amikacin  
 Ciprofloxacin  
 Levofloxacin 
M. marinum  Rifampicin 
 Ethambutol 
 Clarithromycin 
 Cotrimoxazole (CTX) 
 Minocycline (MIN) 
 Doxycycline (DOX) 
   
M. fortuitum  Cefoxitin (FOX) 
 Amikacin 
 Ciprofloxacin 
 Levofloxacin 
 Cotrimoxazole 
 Imipenem (IPM) 
   
M. chelonae  Clarithromycin 
 Tobramycin (TOB) 
 Imipenem 
 Linezolid 
   
M. kansasii  Rifampicin 
 Ethambutol 
 Isoniazid 
   
 
Table A.3– Antibiotics with clinical application for treatment of Buruli ulcer 
 
 
Study Design Population* Intervention Results 
 
Randomized controlled trials: 
  
Double-blind, 
randomized 
controlled trial 
 
Revill WDL, Morrow 
RH, Pike MC, Ateng 
J (1973) 
106 patients from 
Uganda with 
presumed Buruli ulcer 
disease 
 Patients with uncomplicated non-
ulcerated lesions were randomly 
assigned to group A with surgery 
withheld (2/3 of patients) or group B 
with immediate surgery 
 Patients with concerning non-
ulcerated lesions or who requested 
surgery underwent immediate surgery 
(group C), as did patients with 
ulcerated lesions (group D) 
 Patients in all four groups were 
randomly assigned to either CFZ or 
placebo (double-blinding) 
 CFZ alone did not heal any lesions.  
 In patients treated with both CFZ and surgery, CFZ 
did not shorten disease course, reduce number of 
surgeries or extent of scarring. 
 Among patients who received immediate surgery 
(groups B-D), time to healing was associated with initial 
lesion size.  No differences between those treated with 
CFZ versus placebo. 
 Overall recurrence rate was 17%.  Group A had the 
highest proportion of recurrences. 
 CFZ did not prevent recurrences, and M. ulcerans could 
be cultured from lesions after several months of 
treatment. 
Double-blind, 
randomized 
controlled trial 
 
Fehr H, Egger M, 
Senn I (1994) 
18 Ghanaian patients 
with Buruli ulcer 
disease diagnosed 
between February and 
June 1988 
 Intervention: SXT (160mg/800mg) 
tablet twice daily, along with surgical 
resection of large ulcers 
 Control: placebo tablets + surgical 
resection 
 6 patients excluded from analysis: 2 in each group were 
lost to follow-up; the remaining 2 patients were in the 
intervention group and had pneumonia and died of 
tetanus, respectively. 
 All ulcers in the intervention group decreased in size 
and had the largest decreases in size. 
 Lesion growth observed in 3 control patients. 
 In both groups, all patients except for 1 needed one or 
more surgical interventions. 
 During follow-up, there were 2 excisions over a 50-
week period in the intervention group, compared to 4 
excisions in 41 weeks with the control group. 
 Based on these data, the authors suggest that co-
trimoxazole cannot replace surgery as primary 
treatment of Buruli ulcer although adjuvant therapy 
may improve post-operative healing and reduce the 
number or size of further excisions needed. 
Randomized 
controlled trial 
 
Etuaful et al. (2005) 
33 Ghanaian patients 
with presumed Buruli 
ulcer disease enrolled 
between September 
2001 and December 
2002 
 Intervention 1: RIF + STR X 4 wks, 
followed by excision 
 Intervention 2: RIF + STR X 8 wks, 
followed by excision 
 Intervention 3: RIF + STR X 12 wks, 
followed by excision 
 Intervention 4: RIF + STR X 2 weeks, 
followed by excision. 5 patients 
recruited to this group after 
preliminary analysis of above-
mentioned groups  
 Control: immediate excision and 
wound closure 
 2 patients in intervention group 3 withdrew. 
 21 patients had lab-confirmed M. ulcerans infection. 
 All of the patients in the control and intervention 
groups with laboratory-confirmation had culture-
positive lesions at time of excision.  In contrast, none 
of the lesions excised after antibiotics had been given 
for 4 or more weeks were culture positive. 
 Lesions reduced in size with antibiotics, ranging from 
29% reduction in surface area after 2 weeks to 52% 
after treatment for 4 weeks. 
 No side effects reported during antibiotic treatment.  
Laboratory and hearing tests throughout treatment 
remained normal. 
 During 12-month follow-up period, only 1 patient had 
recurrence.  This patient had not received antibiotics. 
BURULICO Trial: 
parallel, open-label 
randomized 
controlled trial 
 
Nienhuis et al. (2010) 
151 patients in Ghana 
with early-stage, 
limited infection with 
M. ulcerans (duration < 
6 months, lesions < 
10cm in diameter) 
 Intervention: 4 weeks of RIF + STR 
followed by 4 weeks of RIF + CLR 
(n=76) 
 Control:  8 weeks of RIF + STR 
(n=75) 
 Participants were followed for 1 year. 
 73 (96%) participants in the intervention arm had 
healed lesions at 1 year, compared to 68 (91) of the 
controls. 
 Median time to healing for category 1 lesions was 18 
weeks and 30 weeks for larger lesions. 
 No one with healed lesions had recurrence. 
 Vestibulotoxic events occurred in 1 and 2 patients in 
the control and intervention arms, respectively. 
WHO-sponsored, 
open-label 
randomized 
controlled trial 
Patients with Buruli 
ulcer disease from 
multiple centers: 1 in 
Benin, 4 in Ghana 
 Intervention: 8 weeks of RIF + CLR 
 Control: 8 weeks of RIF + STR 
 Primary outcomes will be healing without recurrence 
and without surgical excision. 
 Secondary outcomes include rates of recurrence, 
treatment failure, and paradoxical response within 12 
months of treatment initiation. 
Randomized, parallel 
assignment 
intervention study 
Patients with Buruli 
ulcer disease 
 Intervention A: Surgery at week 8 
after antibiotic initiation 
 Intervention B: Surgery at week 14 
after antibiotic initiation 
 Primary outcomes will be healing, extent of surgery 
required, and frequency of functional limitations. 
 
 
 
Pilot studies: 
  
Espey et al. (2002) 41 patients from Côte 
d’Ivoire with  
M. ulcerans infection  
 30 patients completed the 2-month 
trial: 
 Intervention: Dapsone + RIF 
 Control: Placebo 
 Median change in ulcer size was a decrease of 14.0 cm2 
compared to 2.5cm2 in the treatment and control 
groups, respectively. 
 82% of ulcers in treatment group improved compared 
with 75% in placebo group.  No significant difference 
between study groups in treatment effectiveness based 
on clinical evaluation of ulcers. 
Chauty et al. (2011) 30 patients in Benin 
with Buruli ulcer 
disease diagnosed 
between December 
2007 and February 
2009, followed 
prospectively. 
 Treatment: 8 weeks of RIF + CLR  Treatment well tolerated with no adverse events 
reported at 18 months of follow-up. 
 All 30 patients had treatment success within 12 months 
of treatment initiation. 
 15 (50%) healed with antibiotics alone; 11 (37%) 
underwent limited surgical procedures (e.g. curettage or 
excision).  Remaining 4 required extensive surgical 
excision and skin grafting. 
 8 of 10 patients with category I lesions and 5 of 11 with 
category II lesions healed with antibiotics only. 
 
Observational studies: 
  
Lunn HF & Rees 
RJW (1964) 
10 patients from 
Uganda with  
M. ulcerans infection 
 All patients were treated with CFZ for 
varying durations, along with surgical 
excision and skin grafting 
 CFZ helped limit spread of disease and extent of 
surgery needed in 9 of 10 patients. 
Oluwasanmi et al. 
(1976) 
22 patients with Buruli 
ulcer disease in 
Nigeria, of which 19 
were laboratory-
confirmed.   
 All patients treated with surgery, often 
multiple interventions 
 Adjunctive antibiotics used: CFZ, 
STR, SXT 
 9 patients given CFZ alone or CFZ + 
STR 
 3 patients given CFZ + SXT 
 5 patients given SXT alone and 1 
patient given SXT + STR 
 3 cases not treated with antibiotics 
 3 patients developed new lesions while on CFZ. 
 No patient treated with SXT developed new lesions on 
treatment. 
 Adverse effects of antibiotics rare: redness and 
hyperpigmentation seen in 3 patients with clofazimine. 
No other drug reactions. 
Chauty et al. (2007) 224 patients in Benin 
clinically diagnosed 
with M. ulcerans 
infection between Jan 
2003 and Dec 2004, 
followed 
prospectively. 
 Treatment: 8 weeks of RIF + STR 
(n=224) 
 Excluded: 86 patients because of 
pregnancy, immediate surgical 
excision, patient’s decision to receive 
traditional treatment or refusal of 
antibiotic therapy 
 215 patients (96%) had treatment success; of which, 
102 (47.4%) were cured with chemotherapy only. 113 
cases (52.6%) cured with antibiotics and surgical 
excision +/- skin grafting. 
 22 of 27 cases (81%) with ulcers < 5 cm were cured, 
compared with 12 of 57 (21%) with ulcers ≥15 cm 
were cured with antibiotics alone. 
 24 of 53 (45%) with non-ulcerated lesions healed with 
antibiotics only. 
 208 patients seen in follow-up at 1 year after treatment 
completion, and 3 relapses identified. 
O’Brien et al. (2007) 40 patients in 
southeastern Australia 
with M. ulcerans 
infection treated 
between Jan 1998 and 
Dec 2004. 
Retrospective review 
 59 treatment episodes: 29 with surgery 
alone, 26 with surgery and antibiotics, 
and 4 lesions with antibiotics alone 
 Various antibiotic regimens were 
trialed including RIF, CLR, ETH, 
AMK, AZM and CIP 
 Adjunctive antibiotic therapy significantly improved 
rate of treatment success: 16 (100%) of 16 lesions 
healed with antibiotics and surgery, compared with 16 
(73%) of 23 lesions treated with surgery alone. 
 RIF + CIP had 100% treatment success and tolerability 
(no patients ceased treatment), whereas amikacin was 
associated with reduced effectiveness and significant 
toxicity, particularly for elderly patients. 
Schunk et al. (2009) 129 Ghanaian patients 
with M. ulcerans 
infection who received 
surgical treatment 
between Sept 2003 
and Sept 2005. 
Retrospective review 
 79 (61%) patients retrieved for follow-
up.  The group lost to follow-up was 
comparable to study group 
 65 (82%) of 79 patients received 
antibiotics and surgery, but no data on 
antibiotics used or duration available 
in 11 cases. 
 Of remaining 54, 13 received RIF 
only, 1 received STR only, and 40 
treated with RIF +STR 
 Mean duration of therapy was 39.2 +/- 32.4 (SD) days 
for STR and 26.2 +/- 21.4 days for rifampicin. 
 Time interval between treatment and follow-up ranged 
from 4 to 29 months (mean 18 months; median 20 
months). 
 7 (9%) of 79 patients had recurrences detected upon 
follow-up. 
 6 patients reported having developed recurrent lesions 
that were clinically diagnosed as Buruli ulcer and 
surgical removed in time period between excision of 
primary lesion and follow-up. 
Kibadi et al. (2010) 94 patients in 
Democratic Republic 
of Congo with 
clinically diagnosed 
Buruli ulcer disease 
between Oct 2006 and 
Sept 2007, followed 
prospectively 
 Treatment: RIF + STR X 4 wks, then 
surgery followed by additional 8 weeks 
of RIF + STR 
 Only patients with category II and III 
lesions included 
 2 were excluded due to refusal to 
participate or loss to follow-up. 
 61 (66.3%) of 92 had PCR-positive lesions, confirming 
clinical diagnosis. 
 All patients underwent surgical excision after week 4 
except for one PCR-negative patient who refused 
surgery. This patient died 1 month after end of 
treatment due to sepsis. 
 Of 61 patients, 60 (98.4%) had treatment success.  One 
patient had recurrence within 2-year follow-up period. 
Sarfo et al. (2010) 
 
160 Ghanaian patients 
with M. ulcerans 
infection recruited 
between Sept 2005 
and Dec 2007, and 
followed prospectively 
 Treated with RIF + STR X 8 weeks 
 One patient with category III 
ulcerated edema who responded 
poorly to initial regimen received 
additional 4 weeks of RIF + STR 
followed by surgery. 
 Median diameter of lesions declined from 6.4 cm. 
before treatment to 2.1 cm at 4 weeks and to 1.4cm at 
8 weeks. 
 New inflammatory lesions developed in three patients; 
lesions aspirated but cultures were sterile. 
 10 patients offered surgery after antibiotics because of 
unsatisfactory healing, of which 8 patients accepted. 
 All patients had complete healing except for 1 patient 
lost to follow.  The remaining 159 patients also had no 
recurrences at 12-month follow-up period. 
Agbenorku et al. 
(2011) 
189 patients with 
Buruli ulcer from 
Bomfa sub-district of 
Ghana treated from 
Jan to Dec 2005, 
followed prospectively 
 Treatment: RIF + STR X 8 wks, along 
with surgery 
 44 (23.3%) of patients had category 1 lesions and 145 
(76.7%) had larger lesions. 
 All patients had disease resolution. 
 Recurrence identified in only 1 patient after 2 years of 
follow-up. 
Adu EJK, Ampadu 
E, Acheampong D 
(2011) 
132 Ghanaian patients 
with M. ulcerans 
infection treated 
between Sept 2005 
and Sept 2009. 
Retrospective review 
 Treatment: Patients with residual 
lesions after at least 4 weeks of RIF + 
STR selected for surgical treatment 
(wound debridement, excision, skin 
grafting, contracture release and flap 
repair) 
 Prior to antibiotics, 7.4, 41.5 and 59.1% of lesions were 
category I, II and III, respectively. 
 At time of surgery, after 4-8 weeks of antibiotics, 
distribution of lesions was 16.3, 34.1 and 49.6%, 
respectively, for category I, II and III lesions. 
 At time of surgery, most lesions were in healing phase 
and required less extensive surgery.  
Kotey NK & 
Ampadu X (2011) 
68 Ghanaian patients 
with M. ulcerans 
infection  
 Treated with RIF + STR X 8 weeks  Average durations of primary wound healing were 29, 
52, and 65 days for category I, II and III lesions. 
 Statistically significantly differences in duration of 
wound healing among categories. 
O’Brien et al. (2012) 147 patients with  
M. ulcerans infection 
treated between 
March 1998 and May 
2010 in south-eastern 
Australia 
 133 patients followed for 12 months 
after treatment initiation; 4 patients 
had 2 lesions, for total of 137 lesions 
 14 patients excluded because of death, 
loss to follow-up or ongoing follow-
up 
 61% received RIF+CIP, 23% received 
RIF+CLR; of remaining, 4 received 
CIP + CLR, and 2 received RIF + 
MXF 
 47 (34%) lesions treated with surgical excision alone, 
while 90 (66%) treated with antibiotics and surgery 
 Proportion of cases receiving antibiotics increased pre-
2005 compared to post-2005, from 45 to 74%. 
 No treatment failures among those receiving antibiotics 
and surgery, compared with 14 (30%) of 47 treated 
with surgery alone who failed treatment. 
 Complication rates comparable for RIF (GI 
intolerance, hepatitis, rash, hypoglycemia), CIP (GI 
intolerance, joint/tendon effects, rash, hallucinations) 
and CLR (GI intolerance, hepatitis, palpitations). 
Saka et al. (2012) 119 patients in Togo 
with Buruli ulcer 
disease between June 
2007 and Dec 2010 
 All patients treated with RIF + STR X 
8 weeks 
 30 patients received surgery 
 7 patients had complications including superinfection, 
osteomyelitis and bleeding.  3 patients had amputations. 
 12 patients lost to follow-up after 6 months. 
 Of the remaining patients, 10 had functional 
limitations, but no recurrences were observed. 
 
Case series: 
  
Pettit JHS, Marchette 
NJ, Rees RJW (1966) 
4 patients from 
Malaysia with clinical 
or proven M. ulcerans 
infection 
 Case 1: 5-year-old girl treated with 
CFZ for at least 5 months 
 Case 2: 3-year-old boy treated with 
CFZ for 5 weeks 
 Case 3: 4-year-old boy treated with 
CFZ for 6 months 
 Case 4: 27-year-old woman treated for 
3 ½ months with CFZ 
 Cases 1 and 4 were microbiologically proven M. ulcerans 
infection, while cases 2 and 3 were clinically presumed. 
 Complete healing seen in all four patients. 
 Diarrhea and skin discoloration were adverse effects 
associated with CFZ. 
Reid IS (1967) 13 patients from 
Papua treated between 
Sept 1964 and Oct 
1965, of which 6 were 
presumed and 7 with 
laboratory 
confirmation. 
 Case 4: 6-week-old boy was started on 
pencillin and chloramphenicol, and 
then taken for excision and grafting.  7 
days after surgery, ulcer was larger, so 
started dapsone + STR for 5 weeks 
with additional small full-thickness 
graft 
 Case 5: 6-year-old girl with partial 
surgical excision, then 
chloramphenicol + dapsone until skin 
grafting performed.  Subsequently 
treated with dapsone, penicillin and 
STR but continued spread of lesion.  
Then treated with heat therapy 
 Case 8: 12-year-old boy treated with 
penicillin + STR and then taken for 
surgical excision with grafting. Also 
received heat therapy 
 Case 4 used dapsone + STR to arrest ulcer spread and 
allow complete healing within 5 weeks of treatment 
initiation. 
 Cases 5 and 8 had complete healing. 
Goutzamanis JJ & 
Gilbert GL (1995) 
8 patients with  
M. ulcerans infection in 
Melbourne, Australia 
between 1968 and 
1993. 3 patients did 
not have 
microbiological 
confirmation. 
Retrospective review 
 All patients underwent excision and 
either primary closure or skin grafting.  
 3 patients received antibiotics:  
o STR 
o STR+RIF, and 
o RIF+INH+ETH+PZA 
 Susceptibility patterns obtained for 4 of 5 positive M. 
ulcerans cultures: 
o Susceptible to STR, RIF; Resistant to INH, ETH 
o Susecptible to STR, RIF, ETH; Resistant to INH, 
PAS 
o Susceptible to STR, RIF; Resistant to INH, ETH, 
PZA 
o Susceptible to RIF; Resistant to INH, ETH 
 One patient had disease progression despite antibiotics 
and surgery, which responded to adjunctive heat 
therapy. 
Ouoba K, Sano D, 
Traore A, Ouedraogo 
R, Sakande B, Sanou 
A (1998) 
6 patients from 
Burkino Faso with 
presumed Buruli ulcer 
disease diagnosed 
between 1991 and 
1996 
 Case 1: 23-year-old woman treated 
with RIF X 3 months, and surgical 
excision and debridement 
 Case 2: 22-year-old man with CIP X 2 
wks, acetic acid treatment and skin 
grafting 
 Case 3: 10-year-old boy received 
amoxicillin X 2 weeks, nystatin X 10 
days, and metronidazole X 6 days, 
along with acetic acid treatment and 
skin grafting 
 Case 4: 11-year-old boy treated with 
ampicillin + metronidazole X 1 month 
 Case 5: 7-year-old boy treated with 
gentamicin + metronidazole X 3 
weeks, with amputation 
 Case 6: 8-year-old girl treated with RIF 
X 3 months 
 Cases 1-3 and 5 had complete healing. 
 Case 4 was lost to follow-up. 
 Case 6 died of sepsis. 
Journeau P, Fitoussi 
F, Jehanno P, 
Padovani J-P, 
Penecot G-F (2003) 
3 pediatric patients 
diagnosed with Buruli 
ulcer disease in France 
between 1995 and 
2000 
 Case 1: 9-year-old boy originally from 
Côte d’Ivoire.  Treated with multiple 
excisions, skin grafting and RIF + 
CLR X 6 months 
 Case 2: 9-year-old boy originally from 
Côte d’Ivoire.  Treated with wide 
excisions and skin graft. Also received 
RIF + CLR X 6 months 
 Case 3: 10-year-old boy from Mali. 
Treated with wide excision, skin 
grafting and RIF + CLR X 6 months. 
 All 3 cases had complete healing with surgery and 
antibiotics.  No recurrence seen over 5-year, 18-month 
and 1-year follow-up periods for Cases 1, 2 and 3 
respectively. 
Coloma JN, 
Navarrete-Franco G, 
Iribe P, Lopez-
Cepeda LD (2005) 
2 patients from 
Central Mexico with 
M. ulcerans infection 
 Case 1: 76-year-old woman treated 
with INH + RIF X 1 month, then RIF 
stopped due to hepatitis.  After LFTs 
normalized, treatment reinitiated with 
ETH + STR for 60 days. 
 Case 2: 23-year-old man treated with 
RHZE X 2 months, then surgical 
excision of nodules.  Additional STR 
+ ETH X 90 days, then RIF + ETH 
X 10 months 
 Case 1 had complete healing of all 10 nodules (between 
2 and 4 cm in diameter) and 7 ulcers (between 2 and 10 
cm in diameter). 
 Case 2 had healing of all cutaneous lesions (10 ulcers 
between 1 and 5cm in diameter). 
Guerra et al. (2008) 8 patients with  
M. ulcerans infection in 
Peru. 3 patients lost to 
follow-up. 
 Cases 1, 2 and 5 lost to follow-up 
 Case 3: RIF + ETH X 5 wks; abx d/c 
for hepatotoxicity. Then, CIP + TMP-
SMX X 15 days. 
 Case 4: initially diagnosed with 
leismaniasis and treated with sodium 
stibogluconate, but developed new 
lesions and treated with herbal 
medicine.  Then diagnosed as Buruli 
ulcer. Lesions improved after drainage 
so no other treatment initiated. 
 Case 6: RHZE X 6 months and 
surgery 
 Case 7: RIF + STR X 8 wks and 
surgery 
 Case 8: RHZE and surgery. Then 4 
months of MIN + CIP + SXT 
 Case 3 had 2 lesions on both knees, and 8 months after 
start of treatment, only a small ulcer remained on right 
knee.  Complete remission of lesions seen at follow-up 
visits 3 and 5 years after diagnosis. 
 Case 4 was treated with herbal treatments until total 
cure. No recurrence at 5-year follow-up. 
 Cases 6 – 8 had complete resolution without recurrence 
after 2 years of follow-up. 
Gordon et al. (2010) 4 patients with M. 
ulcerans infection in 
coastal Victoria, 
Australia. 
 Case 1, 2: RIF + MXF X 6 wks, prior 
to surgery, followed by 6 additional 
weeks of antibiotics 
 Case 3: RIF + CLR X 4 wks, prior to 
surgery, followed by 3 additional 
weeks of antibiotics 
 Case 4: RIF + CLR X 8 wks, without 
resection 
 Cases 1, 2 and 3 had complete resolution of lesions 
with no recurrence at 36, 13 and 12 months, 
respectively. 
 In case 4, the ulcer had reduced to a small palpable 
nodule at end of treatment course.  Then, 4 weeks after 
stopping antibiotics the lesion became inflamed and 
spontaneously drained. Culture of drainage was culture-
negative, suggesting this represented an immune-
mediated “paradoxical reaction”. 
Kouame et al. (2010) 8 patients from Côte 
d’Ivoire with  
M. ulcerans infection 
involving the face 
 6 patients received RIF + OFX for 3 
to 6 months, along with enoxaparin 
for 2 months 
 2 patients received KAN + RIF, as 
well as enoxaparin. 
 Two patients with non-ulcerative lesions cured without 
any sequelae; 6 patients with ulcerated disease cured 
with sequelae. 
 No disaggregation of outcomes by treatment regimen. 
Nakanaga K, 
Hoshino Y, Yotsu 
RR, Makino M, Ishii 
N (2011) 
19 Japanese patients 
with Buruli ulcer 
disease 
 All patients treated with various 
antibiotic regimens, the most common 
shown here: 
o Single-drug: CLR (n=2) 
o Two-drugs: RIF+CLR (n=2),  
o 3-drugs: RIF+CLR+LVX (n=3) 
 13 patients underwent surgical 
excision and 9 needed skin grafting 
 Most common antibiotics used were CLR and RIF, 
used in 12 and 9 patients, respectively. 
 In 2 cases, initial choice of antibiotics ineffective and 
were changed. 
 In 2 other patients, antibiotics discontinued due to 
adverse effects. 
 All patients had healing with no relapse at at least 3-
months of follow-up. 
 M. ulcerans subsp. Shinshuense identified in all patients.  
In vitro susceptibilities of these isolates to STR, KAN, 
and CLR are higher than those of M. ulcerans strains 
from W. Africa. 
Phanzu et al. (2011) 13 patients from the 
Democratic Republic 
of Congo with 
clinically diagnosed 
with M. ulcerans 
infection involving the 
face 
 10 patients with laboratory 
confirmation of Buruli ulcer disease 
 9 patients treated with RIF + STR, 
then surgery 
 3 patients treated with surgery only, 
and 1 with antibiotics alone 
 Antibiotic duration between 60 and 90 days 
 Clinical response to antibiotics seemed to be associated 
with disease stage: earlier-stage lesions had better 
responses. 
 1 patient of the 10 treated with antibiotics had relapse, 
although could not rule out possible paradoxical 
reaction. 
 
Case reports: 
  
Delaporte E, 
Alfandari S, Piette F 
(1994) 
30-year-old pregnant 
woman with HIV 
diagnosed with M. 
ulcerans infection from 
Democratic Republic 
of Congo 
 Treated with INH + RIF + ETH X 2 
months, then treated with RIF + CLR 
X 5 months. 
 Patient’s CD4 count > 500/mm3 
 Rapid remission of lower extremity lesion with 
complete healing in 8 months. 
 No relapse in 6-month period after antibiotics 
completed. 
Farber ER & Tsang 
A (1967) 
20-year-old Peace 
Corp volunteer with 
probable Buruli ulcer 
disease after return 
from 20-month stay in 
Nigeria 
 Treated with numerous antibiotics 
without improvement. Then 
underwent amputation and treated 
with CFZ 
 Given no improvement with antibiotics, patient 
underwent amputation but postoperatively had wound 
dehiscence so was treated with CFZ.  No data on 
response to CFZ. 
Song M, Vincke G, 
Vanachter H, 
Benekens J, Achten 
G (1985) 
22-year-old patient 
with M. ulcerans 
infection from 
Democratic Republic 
of Congo 
 Treated initially with SXT, then 
switched to RIF based on culture 
results for 6 months. 
 Fistulous tracts identified and 
minocycline added to rifampin for 
additional 6 months. 
 Dextran polymer applied topically to 
help with wound debridement 
 Lesion healed after 1-year of therapy. 
Tsukamura M, & 
Mikoshiba H, (1982) 
19-year-old Japanese 
woman with  
M. ulcerans infection 
 Treated with 2 weeks of RIF  Initial lesion of 5cm in diameter healed completely. 
Semret M, Koromihis 
G, MacLean JD, 
Libman M, Ward BJ 
(1999) 
36-year-old Canadian 
man with M. ulcerans 
infection after travel 
to northern, West and 
Central Africa.   
 Treated with cloxacillin X 7 days, then 
metronidazole and doxycycline X 10 
days, without benefit 
 Once acid-fast bacilli identified on 
tissue biopsy, started on RIF + ETH 
+ SXT, for 8 weeks.  Then CLR + 
CIP added. Underwent multiple 
debridements 
 5-drug regimen continued for 10 
weeks. ETH stopped due to 
paresthesias.  
 Paresthesias continued for 3 more 
months until CIP and TMP-SMX 
stopped 
 RIF + CLR continued for total of 18 
months 
 In addition to multiple debridements, patient also 
underwent radical excision of the lesion and split 
thickness skin graft about 8 months into treatment. 
 Complete healing of lesion after 18-month treatment 
period. 
 No recurrence within 4-year follow-up period. 
Faber et al. (2000) 40-year-old Chinese 
woman with Buruli 
ulcer disease 
 Treated with RIF + CLR X 2 months. 
Then M. ulcerans strain found to be 
resistant to rifampicin, so switched to 
CIP + RFB X 4 weeks. 
 After 2 months with RIF + CLR, ulcer was nearly 
completely healed with only small defect. Lesion was 
culture-negative at this time. 
 Treated with CIP + RFB for 4 weeks before abx had to 
be stopped due to leukopenia.  
 Ulcer healed with scarring. Several months after 
treatment completed, scarring with erythematous 
induration was excised by patient request (tissue biopsy 
was culture-negative). 
Johnson et al. (2002) 27-year-old HIV-
positive woman with 
disseminated  
M. ulcerans infection 
(including 
osteomyelitis) 
 Initial lesion excised with skin grafting. 
New lesion appeared within months 
and was excised. 3 months of RIF + 
ETH + CLR given.  Continued to 
have disease progression requiring 
multiple debridements and excisions.   
 Disseminated Buruli ulcer disease with multifocal 
lesions and osteomyelitis despite numerous surgical 
excisions and debridements and 3 months of RIF + 
ETH + CLR. 
 Patient left against medical advice to pursue care by 
traditional healers.  Passed away shortly thereafter. 
Pszolla N et al. (2003) 4-year-old boy from 
Angola with 
disseminated  
M. ulcerans infection 
(including 
osteomyelitis) 
 Multiple lesions treated with repeat 
debridements, and RFB + CLR + Pto.  
 Some of the lesions progressed, so 
repeat debridements. RFB + CLR 
continued but Pto stopped and SXT 
added. 
 After 3 months of antibiotics, CLR 
stopped. New metastatic lesions 
developed, and antibiotic regimen 
changed to CLR + RFB 
 5 months into treatment, hyperbaric 
oxygenation therapy (HBO) initiated.  
Within 6 weeks of HBO, wound care 
and antibiotics all lesions had closed 
 Shortly after all lesions appeared to have healed, patient 
found to have osteomyelitis of left distal femur.  
Whole-body scan showed new focus of infection in 
distal part of left humerus. 
 ETH and CFZ added to CLR + RFB.  Antimicrobial 
therapy was ongoing until patient returned to Angola 
and was lost to follow-up. 
Millay et al. (2006) 14-year-old boy from 
West Victoria, 
Australia, with  
M. ulcerans infection 
 Treated with AMK + AZM + RIF, 
along with surgical debridement and 
skin grafting 
 After 3 weeks, patient discharged 
home on RIF + AZM 
 M. ulcerans was cultured from tissue biopsy after 11 
weeks of antibiotics. 
 After 3 months of treatment, wound was healing well 
with residual scarring. 
Kibadi K. (2008) 9-year-old boy with  
M. ulcerans infection 
from the Democratic 
Republic of Congo 
 Treated with surgical excision and 
grafting, and antibiotic course of 
RHZE for 2 months 
 Received steroid taper 
 Patient had healed lesion without recurrence after 6-
year follow-up. 
O’Brien DP, Athan 
E, Hughes A, 
Johnson PD (2008) 
87-year-old woman 
from southeastern 
Australia with  
M. ulcerans infection 
involving 
osteomyelitis 
 Treated with multiple surgical 
interventions and adjunctive antibiotic 
courses. 
 
 Initial right calf ulcer surgically excised with primary 
closure and clean margins. 
 14 days later, new left heel lesion, treated with wide 
excision and free flap. 
 Adjunctive RIF + ETH + AMK + CLR, but new 
lesion on right buttock that was also excised. 
 Had drug reaction to CLR, so abx changed to RIF + 
AMK. AMK stopped due to ototoxicity. 
 Continued on RIF X 4 months, but disease progression 
requiring multiple debridements. CIP added. 
 Patient elected for no further surgery, completed 6 
months of RIF + CIP, with wound healing.  No disease 
recurrence over 36-month follow-up period. 
Ezzedine et al. (2009) 24-year-old Caucasian 
man, returning from 
long-term travel to 
Senegal, with  
M. ulcerans infection 
 RIF + MXF, plan for 12 weeks  Patient lost to follow-up after 15 days of treatment 
initiation. 
Ezzedine et al. (2010) 44-year-old Malian 
visitor to France with 
M. ulcerans infection 
 RIF + CLR, plan for 8 weeks  Patient returned to Mali and lost to follow-up. 
Kibadi et al. (2010) 35-year-old man with 
HIV in Democratic 
Republic of Congo 
 RIF + STR for 12 weeks  After 8 weeks of antibiotics, enlargement of all lesions 
observed and development of new ulcer. Antibiotics 
continued for additional 4 weeks. 
 Patient died 2 weeks after treatment completed, just 
when ARV scheduled to begin. 
Minime-Lingoupou et 
al. (2010) 
2 patients from the 
Central African 
Republic diagnosed 
with M. ulcerans 
infection 
 Case 1: 62-year-old man with large 
ulceration of right lower extremity.  
Died of unknown case before 
treatment could be started 
 Case 2: 62-year old man with left ankle 
ulceration treated with RIF + STR X 8 
weeks. 
 The second patient’s lesion had receded in size after 8 
weeks of antibiotics. 
 First case report of Buruli ulcer disease in Central 
African Republic. 
Watanabe et al. (2010) 46-year-old man 
Japanese man with 
Buruli ulcer disease 
 Treated initially with steroids. After 
diagnosis as Buruli ulcer, treated with 
LVX + CLR for unspecified duration, 
followed by debridement and skin 
graft closure. 
 Initial lesion misdiagnosed as insect bite and treated 
with steroids. Had improvement at first but then 
worsening of ulcer, so underwent skin biopsy.  
Histopathology showed dense neutrophilic infiltration 
so presumed neutrophilic dermatosis and steroids 
resumed.  Lesions gradually formed painless ulceration 
with necrotic mass, and AFB identified using direct 
smear examination. PCR positive for M. ulcerans.  
 Treated with LVX + CLR, disease progression halted. 
 Given poor epithelization/healing, patient underwent 
debridement and skin graft closure 
 No recurrence during 6-month follow-up period. 
Onoe et al. (2012) 52-year-old Japanese 
woman with  
M. ulcerans infection 
 Initial lesion: CLR + RIF + LVX X 6 
wks, then surgery 
 Recurrent lesion: CLR + RIF X 10 
weeks 
 No improvement in facial ulcer after 6 weeks of 
antibiotics so patient underwent excisional surgery. 
 Then developed recurrent lesion, with reduction in size 
by half after antibiotics. 
Tsukagoshi S, Dehn 
TCB (2012) 
9-month-old boy in 
Uganda with 
presumed Buruli ulcer 
 Right forearm edema (Ziehl-Neelson 
staining negative): gentamicin, 
metronidazole and ceftriaxone initially.  
Then underwent multiple surgeries, 
and started on RIF + INH (only 
preparation of RIF available; STR not 
available) 
 Right forearm edema evolved into 3 ulcers with 
undermined edges. Multiple debridements in first 10 
days after presentation, with improvement in lethargy 
and appearance of wounds.  Lesions reduced in size by 
50% with antibiotics.  However, diagnosed with 
osteomyelitis of distal radius and transferred to another 
hospital for planned sequestrectomy with skin grafting.  
* Buruli ulcer cases were laboratory-confirmed unless otherwise specified. 
Abbreviations: amikacin, AMK; azithromycin, AZM; ARV, antiretrovirals; ciprofloxacin, CIP; clarithromycin, CLR; clofazamine, CFZ; levofloxacin, 
LVX; minocycline, MIN; rifabutin, RFB; rifampin + isoniazid + pyrazinamide + ethambutol, RHZE; rifampicin, RIF; rifapentine, RFP; streptomycin, 
STR; co-trimoxazole, SXT 
Table A.4 – Drugs not suitable for application in the treatment of Buruli ulcer disease 
 
Drug 
Activity against  
M. ulcerans 
Route of 
administration 
Contraindications Side effects Other 
Isoniazid No   Hepatitis  
Ethambutol No     
Pyrazinamide No   Hepatotoxicity  
Streptomycin Yes Injectable Pregnancy category D Ototoxicity; nephrotoxicity  
Kanamycin Yes Injectable Pregnancy category D Ototoxicity; nephrotoxicity  
Amikacin Yes Injectable Pregnancy category D Ototoxicity; nephrotoxicity  
Capreomycin No clear activity Injectable Pregnancy category C Ototoxicity; nephrotoxicity  
Viomycin No data Injectable Pregnancy category C Ototoxicity; nephrotoxicity  
Sparfloxacin    
Phototoxicity – Withdrawal 
from U.S. market 
 
Cycloserine 
Weak activity in animal 
models 
 Pregnancy category C CNS toxicity Difficult procurement 
Terizidone 
No data available, but as a 
different formulation of 
cycloserine, anticipate 
would have weak activity 
  CNS toxicity Difficult procurement 
Ethionamide No     
Prothionamide No data  Pregnancy category C 
Severe GI intolerance; 
Hepatic dysfunction, 
Difficult procurement 
PAS No   GI disorders, hepatotoxicity  
Thioacetazone No   GI disorders  
      
Clofazimine 
In vitro activity, but no 
convincing evidence of 
efficacy in mouse models 
or patients 
 Pregnancy category C Skin discoloration  
Linezolid 
Weak bactericidal activity 
in mouse curative model 
 Pregnancy category C Thrombocytopenia High cost 
Minocycline 
Weak bacteriostatic activity 
in mouse footpad 
preventive model 
 
Pregnancy category D. 
Not recommended in 
children <8 years old 
  
Doxycycline No data  Pregnancy category D.   
Drug 
Activity against  
M. ulcerans 
Route of 
administration 
Contraindications Side effects Other 
Not recommended in 
children <8 years old 
Imipenem No data  Injectable    
Meropenem-
clavulanate 
No data  Injectable    
Cefoxitin No data Injectable    
Tobramycin No data Injectable    
Telithromycin 
Moderately susceptibility in 
vitro. Weak bacteriostatic 
activity in mouse model 
    
PA-824 No      
Abbreviations: CNS, central nervous system; GI, gastrointestinal; U.S., United States. 
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